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Compounds containing the quinoline moiety have been the mainstay of antimalarial 
chemotherapy. However, the emergence of resistant strains of Plasmodium 
falciparum, the causative agent of malaria, has compromised the efficacy of these 
antimalarial quinolines. Therefore the development of new efficient drugs is of critical 
importance. Extensive research has identified the cysteine proteases in malaria and 
other parasitic diseases as potential targets for new chemotherapy due to their critical 
roles in the life cycles of the causative agents. 
Due to their role in the antimalarial activity of clinically available drugs, quinolines 
were used as scaffolds to which electrophilic groups, such as thiosemicarbazone, a,~­
unsaturated ketone and pyrazoline moieties were appended. A series of quinoline 2-, 
3-, 4- and 8-thiosemicarbazones were prepared by condensation of 
quinolinecarboxaldehydes or acetylquinolines with thiosemicarbazide. N 1 NIh-
substituted thiosemicarbazones were also prepared by reaction of thiosemicarbazone 
thioesters with primary and secondary amines. The product yields ranged from low, 
moderate to excellent. Another series of compounds, the chalcones were prepared via 
the Claisen-Schmidt condensation of aromatic aldehydes and methyl ketones. These 
were further converted into pyrazoline derivatives by reaction with hydrazine hydrate. 
Pyrazoline derivatives were further reacted with substituted aromatic sulfonyl 
isocyanates to produce N-substituted pyrazole sulfonyl ureas. The product yields 
ranged from low, moderate to excellent. All compounds were characterized by 
spectroscopic and analytical techniques. 
The thiosemicarbazones were then evaluated for inhibition of parasitic cysteine 
proteases falcipain-2 (from Plasmodium falciparum), cruzain (from Trypanosoma 
cruzi) and rhodesain (from Trypanosoma brucei) and also for in vitro activity against 
the chloroquine resistant strain (W2) of P. falciparum. Most of the compounds were 
not efTective against falcipain-2, but some were weak inhibitors, with N' -quinolin-2-
yl-ethylene-thiosemicarbazone (59) showing modest activity against the W2 strain. 
On the other hand, N' -quinolin-2-yl-methylene-l ' -(3-dimethylamino-l-propylamine)-
thiosemicarbazone (49) and N' -quinolin-3-yl-methylene-l ' -(3-dimethylamino-l-
propyl amine )-thiosemicarbazone (52) were weak inhibitors of the growth of W2 











there was no correlation between the ability of the compound to inhibit falcipain-2 
and antiplasmodial activity against W2 in vitro. This suggests that falcipain-2 is not 
the target of these compounds. Structure activity relationship (SAR) data against 
cruzain and rhodesain is interesting, because a number of compounds 
(thiosemicarbazones) that were not effective against falcipain-2 were potent in the low 
micromolar range. Compounds such as N' -quinolin-4-yl-methylene-
thiosemicarbazone (38) and N' -(2-Chloro-8-methyl)-quinolin-3-yl-methylene-
thiosemicarbazone (48) were the most effective against cruzain. Against rhodesain, 
more compounds were effective as compared to cruzain. Compounds such as 38, N'-
quinolin-2-yl-methylene-thiosemicarbazone (42), N' -(2-chloro-6-methoxy )-quinolin-
3-yl-methylene-thiosemicarbazone (44), N' -(2-chloro-8-methyl)-quinolin-3-yl-
methylene-thiosemicarbazone (48) and N' -quinolin-2-yl-ethylene-thiosemicarbazone 
(59) were the most effective against rhodesain. Nl NI-b-substitution was found to 
lower the potency of the thiosemicarbazones against both cruzain and rhodesain. 
The chalcones and pyrazolines were evaluated against a chloroquine sensitive strain 
(010) of P. falciparum. All these compounds lacked potency against the DlO strain at 
the chosen concentrations, and the biological data obtained was inconsistent to make 











































Adenosine 5'triphosphate Binding Cassette 




















Chemical shift (in NMR) 
doublet (in NMR) 
double of doublets (in NMR) 





























































High Resolution Mass Spectrometry 
Hertz (in NMR) 
Iodo 
Inhibitory concentration to inhibit 50 % of enzyme activity or 
parasite growth 
Infrared 






Moles per cubic decimeter (mol/dm') 







































































P-glycoprotein homolog 1 
Triphenyl phosphine 
parts per million (in NMR) 
Isopropanol 
quartet (in NMR) 
Retention factor (in chromatography) 
Room temperature 






Sulfur trioxide pyridine complex 


















thin layer chromatography 













T ABLE OF CONTENTS 
CHAPTER 1. INTRODUCTION ........................................................... 1 
]. Malaria .................................................................................... 1 
1.] Disease .................................................................................... 1 
1.2 Plasmodium life cyclc .................................................................. l 
1.3 The Plasmodium food vacuole ......................................................... 5 
1.4 Chemotherapy ........................................................................... 6 
1.5 Mode of action of chloroquine ........................................................ 9 
CHAPTER 2. CYSTEINE PROTEASES AND THEIR INHIBITORS ....... 11 
2.1. Parasitic cysteine proteases .......................................................... 11 
2.2. Malarial and Trypanosomal cysteine proteases ................................... 16 
2.3. Inhibition of cysteine proteases ...................................................... 17 
2.3.1. Classification of cysteine protease inhibitors .......... , ......................... 18 
2.4. Inhibitors of malarial and trypanosomal cysteine proteases ..................... 23 
CHAPTER 3. SYNTHESIS AND CHARACTERIZATION OF TARGET 
COMPOUNDS ............................................................................ 26 
3.1. Quinoline thiosemicarbazones ...................................................... 26 
3.1.1. Background and rationale ......................................................... 26 
3.1.1.1. Background on Quinoline compounds ........................................ 26 
3.1.1.2. Background on Thiosemicarbazones .......................................... 27 
3.1.1.3. Rationale on Quinoline thiosemicarbazones ................................. 31 
3.1.1.4. Synthesis and Characterization ................................................ 34 
3.2. Chalcones and pyrazolines ......................................................... .42 
3.2.1. Background and rationale ........................................................ .42 
3.2.1.1. Background on chalcones derivatives ........................................ .42 
3.2.1.2. Background on pyrazoline derivatives ....................................... .44 
3.2.1.3. Rationale for Pyrazoline derivatives as Potential Antimalarial 
agents ........................................................................................ 45 











CHAPTER 4. BIOLOGICAL RESULTS AND DISCUSSION ............... 55 
4.1 Data against Cysteine proteases (Falcipain-2, Cruzain, Rhodesain), and 
chloroquine resistant W2 strain of P. falciparum .................................... 55 
4.1.1. Thiosemicarbazones: Falcipain-2 and P. falciparum SAR .................. 56 
4.1.2. Thiosemicarbazones: Cruzain and Rhodesain SAR ........................... 56 
4.1.3. Compliance to Lipinski's Rule ................................................... 60 
4.2. Data against the chloroquine sensitive strain (010) of Plasmodium 
jalciparum .... ........ '" .................................................................. 61 
4.2.1. Pyrazoline Analogues of Chalcones ............................................ 62 
4.3. Conclusion ............................................................................ 62 
CHAPTER 5. EXPERIMENTAL ................................................... 64 
5. 1. GeneraL ................................................................................ 64 
5.2. Biology ................................................................................. 66 
5.2.1. Thiosemicarbazones ............................................................... 66 
5.2.2. Chalcones and Pyrazoline derivatives ........................................................ 67 
5.3. Chemistry .............................................................................. 68 
















Malaria is a protozoal disease transmitted by the Anopheles mosquito, caused by 
minute protozoa of the genus Plasmodium. It occurs in most tropical and 
subtropical regions. Malaria is a very old disease, which is reported to have 
originated from Africa. It then spread to other regions of the world such as the 
Mediterranean, India and South East Asia through human migration. A large 
number of fatalities and death rates due to malaria are reported in Africa. I -] 
It is estimated that malaria affects 300-400 million people worldwide, with close 
to 2 million deaths reported annually; most of which are children under the age of 
five years from Africa. Human malaria is caused by four species of the 
Plasmodium namely; Plasmodium vivax, Plasmodium malariae, Plasmodium 
ovale and Plasmodium Jalciparum. Of the four species of Plasmodium; 
Plasmodium Jalciparum is the most virulent and deadly malaria parasite and it is 
responsible for the most malaria cases that lead to death.1,2 The malaria parasite 
requires two hosts; the human and a female Anopheles mosquito in order to start 
its complex life cycle.2 
1.2 Plasmodium Jalciparum life cycle 
The Plasmodium complex life cycle begins within the female Anopheles 
mosquito, where it undergoes a development stage which requires a blood meal to 
mature its eggs. Therefore the Plasmodium life cycle really begins when the 
infected female mosquito bites a human host, withdrawing blood while injecting 
sporozoite-containing salivary glands.2•3 The sporozoites first circulate in the 
blood for a short period of time, before settling in the liver. In the liver they enter 
the liver cells (parenchymal cells) and multiply to form merozoites. This stage of 
the life cycle is called the pre-erythrocytic schizogony. After about 5 days the 
parenchymal cells rupture and release the merozoites into the red blood cells 
(erythrocytes). The red blood cells provide the parasite with a safe environment 










Chapter I Introduction 
P. vivax and P. ovale have a continuing liver cycle, while on the other hand P. 
Jalciparum does not have a continuing liver cycle.3 In the red blood cells the 
parasites develop into two forms, the sexual and an asexual. The asexual form 
produces schizonts which contain merozoites. The merozoites cause the infected 
red blood cells to rupture. The merozoites are then released from the infected red 
blood cells and they invade new red blood cells. The merozoites develop through 
the so-called ring, trophozoite and schizont stages.2-4 On the other hand, the sexual 
form produces the male and female gametocytes in the blood stream, and these are 
ingested by the female mosquito when it feeds from the infected human host.2-4 
The male and female gametocytes fuse in the mosquito's gut and pass through the 
gut wall where they develop into oocysts. The oocysts develop over a period of 
days and release sporozoites that migrate to the salivary glands which are passed 
onto another human host when the mosquito takes another meal.2,3 This is 
illustrated in figure I. 
In P. vivax, P ovale and probably P. malariae, all stages of development 
subsequent to the liver cycle can be observed in the peripheral blood. In the case 
of P. Jalciparum only ring forms and gametocytes are observed in the peripheral 
blood. The developing forms appear to stick in the blood vessels of the large 
organs such as the brain and restrict blood flow with serious consequences. P. 
Jalciparum invades red blood cells of all ages whereas P. vivax and P. ovale prefer 
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PLASMODIUM lIFE CYCLE 
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Figure 1. Life Cycle of Plasmodiumjalciparum8 
Parasite growth in the red blood cells is supported by the ingestion of host 
hemoglobin.s Hemoglobin comprises 95 % of the cytoplasmic protein of the red 
blood cells, and the malaria parasites degrade 60-80 % of the hemoglobin for 
nutrition during the intraerythrocytic cyc1e.6 In P. Jalciparum hemoglobin 
degradation occurs predominantly in trophozoites and early schizonts, stages 
where the parasites are highly metabolically active. Hemoglobin degradation is an 
ordered, complex process. Hemoglobin is taken by trophozoites into the parasite's 
acidic food vacuole, analogous to lysosomes.s,7 In the food vacuole it becomes a 
substrate for numerous proteolytic enzymes, which break it down into heme, a 
major component of the malaria pigment (hemozoin), and globin which is 
hydrolyzed into its amino acids for the parasite's nutrition.s,7,8 The degradation 
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figure 2: Schematic representation of degradation of hemoglobin for the parasite's 
nutrition 
The amino acids produced from globin are incorporated into parasite proteins. On 
the other hand the four equivalents of reduced heme, ferriprotoporphyrin IX 
[Fe(JI)PPIX] are produced with oxygen. Ferriprotoporphyrin contains iron, a 
metal that can be oxidized to a ferric (Fe3~) state or reduced to a ferrous (Fe2r) 
state. It is the reduced heme that can transport oxygen. The molecular oxygen 
accepts an electron from the reduced heme, Fe(I1)pPIX to initiate a chain of 
oxygen radical metabolism. The Fe(II)pPIX is then oxidized to Fe(I1I)PPIX 
(hematin), and this is toxic to the microorganisms of the parasite in its free form. 
Therefore the parasite detoxifies the Fe(lII)PPIX by forming a malaria pigment, 
also known as hemozoin. Hemozoin appears to contain dimerized heme. It is the 












Chapter 1 Introduction -------' 
1.3 The Plasmodium food vacuole 
The Plasmodium food vacuole is a special organelle optimized for hemoglobin 
degradation. It is acidic; hence it is a site for a number of processes such as 
acidification, hemoglobin proteolysis, peptide transport, heme dimerization, 
detoxification of oxygen radicals and quinoline action. A number of proteins in 
the food vacuole are known, and these include aspartic, cysteine and 
metalloproteases, an ATP-binding cassette (ABC) transporter, an ATPase, a heme 
polymerase, and several oxidant enzymes. 12 
There are four distinct proteases in the food vacuole, which act in an ordered 
fashion in hemoglobin degradation as depicted in figure 2. Two aspartic proteases, 
plasmepsins I and II appear to initiate the degradation process. A cysteine 
protease, tilJcipain-2, plays a vital downstream role after the initiation by 
plasmepsins. A metalloprotease, falcilysin, functions further downstream to the 
above-mentioned proteases.12 Plasmepsins have a pH optima near 5, and this is 
consistent with their environment in the acidic food vacuole. 13,14 While it is only 
aspartic protease inhibitors that effectively block the initial steps of hemoglobin 
degradation, a cysteine protease is also implicated in the initial stages of 
hemoglobin degradation. This implication is due to the observation of swollen 
food vacuoles filled with undegraded globin when the parasites are treated with 
cysteine protease inhibitors. ls-18 It is possible that there could be an accumulation 
of erythrocyte glutathione in the food vacuole and a highly reducing environment 
that would rapidly denature hemoglobin, thus causing the falcipain-2 to function 
early in the process.19.20 
FaJcilysin, a zinc metalloprotease, is determined to function downstream of the 
plasmepsins and falcipain-2 in the hemoglobin degradation pathway. Falcilysin 
does not cleave hemoglobin or globin, but it degrades fragments of hemoglobin 
that are generated by the plasmepsin 11.21 The acidic conditions of the Plasmodium 
food vacuole are most likely maintained by an ATP-driven proton pump, 
homologous to the lysosomes.22 ATPase activity has been found to be enriched in 
the food vacuole membranes.23,24 Several genes homologous to the ABC 
transporter family have been found in the P. falciparum. 25.26 One of these genes, 











Chapter 1 Introduction 
is in the food vacuole membranes. Pgh 1 looks like a typical ABC transporter, 
with twelve transmembrane domains and two hydrophobic domains with 
nucleotide binding capabilities. Pgh I has been shown to be capable of binding 
ATP, ADP, and GDP.27 Pgh 1 is presumed to mediate transport across the food 
vacuole, because similar mammalian ABC transporters can act as energy-
dependent transporters that efflux drugs in multidrug resistance (MDR) tumor 
cells.28 
The Plasmodium food vacuole is much like the nuclear reactor. It generates food 
for the parasite by means of amino acids from the globin, yet on the other hand it 
produces toxic products such as heme which is toxic to the parasite. Thus a valid 
approach for the development of antimalarial chemotherapy, is the inhibition of 
the hemoglobin degradation within the food vacuole. 12 Therefore for the design 
and development of inhibitors, the acidic environment of the food vacuole must be 
considered for the accumulation of inhibitors inside the food vacuole. 
1.4 Chemotherapy 
Antimalarial drugs have been used for centuries. The first antimalarial drugs were 
alkaloids extracted from the bark of the Cinchona tree.2,J Quinine 1 is one of the 
drugs extracted from the Cinchona tree, and it has been in use for more than three 
centuries. It was the only effective drug for the treatment of malaria. It is the only 
drug that has remained largely effective for treating malaria for over a long period 
of time. Lately, quinine is only used for the treatment of severe Jalciparum 
malaria, partly due to undesirable side effects.3 
In the J 920s methylene blue 2 (figure 3) was shown to have some antimalarial 
activity and attempts at the design and preparation of synthetic antimalarial drugs 
were initiated. Analogs of methylene blue were then prepared by replacing one 
methyl group with a basic side chain, and this enhanced the activity against 
malaria. It was then believed that the basic side chain was critical for antimalarial 
activity, and this led to the synthesis of plasmoquine, which was later called 
pamaquine 3. Pamaquine was first used in 1926 and it was capable of radical cure. 
However, later it was found to be toxic, and a less toxic analog primaquine 4 was 
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used to eradicate the refractory hypnozoites (liver reservoirs) of P. vivax and P. 
ova/e.2 
~A 
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Figure 3: Structures of some antimalarial drugs 
Following the discovery of quinine, extensive efforts including the screening of 
thousands of compounds have led to the development of a number of effective 
synthetic antimalarial drugs. The most important of these drugs is chloroquine 5, a 
4-aminoquinoline that is effective for both treatment and prophylaxis. Chloroquine 
was first used in the 1940s shortly after the Second World War. It was effective in 
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eradicated. It has advantages such as minimal toxicity to the human host, and it is 
widely available at low cost throughout the world.2,3 Unfortunately nowadays, 
most strains of Jalciparum malaria are resistant to chloroquine, and more recently 
strains of resistant viva\" malaria have been reported. Malaria resistance to 
chloroquine has rendered its use for presumptive treatment ofJalciparum malaria 
and chemoprophylaxis inappropriate. No other antimalarial is as safe and effective 
as chloroquine. Quinine remains the best antimalarial drug for the treatment of 
chloroquine-resistantJalciparum malaria.2 
In the 1930s another antimalarial drug mepacrine 6, a 9-amino-acridine derivative 
was developed. It was used as a prophylactic on a large scale during the Second 
World War, and then it was considered a safe drug. However, now it is considered 
to have too many undesirable side effects, such that its use has been stopped. In 
1946, proguanil 7, a drug which belongs to the biguanide class of compounds was 
synthesized. It has a biguanide chain attached at one end to the chlorophenyl ring. 
Proguanil is a folate antagonist and it destroys the malarial parasite by binding to 
the enzyme dihydrofolate reductase. In some countries it is used as a 
prophylactic.J 
To address the widespread chloroquine-resistant strains of malaria, a few more 
antimalarial agents were developed and synthesized. Among these antimalarial 
agents, metloquine 8, a quinoline methanol derivative that is structurally related to 
quinine was introduced in 1971. It was effective against malaria, and because of 
its long half life it was an effective prophylactic. However, widespread resistance, 
together with undesirable side effects has limited its use. In addition it cannot be 
used with quinine because of the structural relationship?,3 
In the 1940s, halofantrine 9 was identified, but it was only introduced in the 
1980s. It belongs to the class of compounds called the phenanthrene-methanols 
and it is not related to quinine.J It has been used for the treatment of chloroquine-
resistant strains of malaria, but due to its short half life it is not a good 
prophylactic. Its use is now restricted, due to reports of serious cardiotoxicity and 











Efforts to address the burden of chloroquine-resistant malaria were continued, and 
another 4-aminoquinoline, amodiaquine 10 was synthesized. It is a Mannich base 
of chloroquine together with tebuquine 11. These were introduced as alternatives 
to chloroquine and have been used as prophylactics for Jalciparum malaria for 
over 40 years. One of the most promising developments in malaria chemotherapy 
was the discovery of artemisinin 12. It was isolated from the Artemisia annua, a 
plant that is widely used in China to treat fever. 3 
Atovaquone 13 which is approved for the treatment of patients with Pneumocystis 
infections appeared to be effective against malaria when combined with proguani1. 
However, its use has been limited by reerudescence after treatment. Pyronaridine 
14, an acridine derivative used to treat malaria in China, has shown efficacy 
against Jalciparum malaria.29-31 The structures of all these antimalarial drugs are 
shown in figure 3. 
1.5 Mode of action of chloroquine 
Despite its long period in use, the mechanism of action of chloroquine is still a 
subject of intense debate. thus it is still far from being resolved. However, the 
commonly accepted hypothesis is that chloroquine and related quinoline-
containing antimalarial drugs act primarily on heme disposal, a process in which 
intraerythrocytic-stage malaria parasites detoxify heme in the food vacuole.32 
Chloroquine is proposed to interfere with hemozoinl malaria pigment formation, 
by complexing with free heme; thereby creating toxic complexes that result in 
parasite death.2,33 Studies on the crystal structure of ~-hematin, a synthetic 
equivalent of hemozoin suggest that chloroquine is chemiabsorbed onto the 
actively growing crystal faces thereby inhibiting hematin sequestration and 
contributing to the toxic levels of chloroquine-hematin in the cell.8.34 
Numerous theories about the mode of action of chloroquine have emerged, but 
they appear to agree in that chloroquine selectively affects the stages of the 
parasite life cycle after hemoglobin is digested. They also suggest that chloroquine 
selectively accumulates in the food vacuole. Chloroquine is a weak base (pKal 
8.1; pKa2 10.2), and this would explain its selective accumulation in the food 
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can diffuse freely through the membranes. Inside the acidic food vacuole, 
chloroquine becomes doubly-protonated, membrane-impermeable, and thus is 











Chapter 2 Cysteine Proteases and Their Inhibitors 
CHAPTER 2 
CYSTEINE PROTEASES AND THEIR INHmITORS 
2.1 Parasitic cysteine proteases 
Proteases, also termed peptide hydrolases, catalyze the cleavage of amide linkages 
in macromolecular proteins and oligomeric peptides. They have been identified in 
biological systems, from viruses to vertebrates. It is estimated that it could be very 
difficult to hydrolyze a peptide bond without proteases as biological catalysts, and 
hydrolysis could take centuries, whereas a protease can degrade as many as one 
million peptide linkages per second.36 Proteases range from monomers of 10 kDa 
to multimeric complexes of several hundred kDa. They can initiate their catalytic 
activity either within a polypeptide chain (endoprotease activity), or from the 
amino or carboxyl ends (exopeptidase activity).36,37 
The proteases have been divided into groups based on the catalytic mechanism 
used during the hydrolysis of peptide bonds. The main catalytic types are serine, 
threonine, aspartate, metallo and cysteine proteases.36,37 Cysteine proteases of 
parasitic organisms are divided into two main groups referred to as clans, CA and 
CD.36,38 In 1879, the first cysteine protease was purified and characterized from 
Carica papaya, the papaya fruit, and was thus named papain. Since its discovery, 
numerous proteases that have sequences similar to papain have been called 
papain-like. Clan CA, or papain-like proteases are further divided into families. 
Important parasite proteases are located to family C I (cathepsin Band L-Iike), and 
family C2 (calpain-Iike). Other clans and families of pathogenic organisms 
include clan CB and clan CC (viral proteases) and clan CD (family C 13; 
legumain-like ).36 
The majority of parasite cysteine proteases belong to the family Cl within clan 
CA. Members of the CA clan are either targeted to intracellular vesicle 
compartments (these include cathepsins B, C, H, K, Land S), or are secreted and 
thus possess a leader peptide. Clan CA proteases are also characterized by their 



















L-trans-epoxysucciny l-leucy lamido( 4-guanidino )butane 
Figure 4: Structure of a general cysteine protease inhibitor, E64 
Proteases bind peptide substrates in their active site cleft through backbone and 
side chain interactions that lie around several defined pockets in the enzyme 
termed S 1, S2, S3, S4 for those pockets that bind to the corresponding amino acids 
that are N-terminal to the scissile amide bond while the S I', S2', S3', S4 'pockets 
bind to the amino acids C-terminal to the scissile bond. The corresponding side 
chains in the peptide substrate are termed PI, P2, P3, P4 and PI', P2', P3', 
P4' .36,39 This is illustrated in figures 5A and 5B. 
A PROTEASE 
N~ --- -- ·· COOH 
PEPTIDE SUBSTRATE 
Figure SA: Schematic presentation of the peptide substrate interaction with the active site 
pockets of the cysteine protease. Amino acids from the peptide are denoted by "P" and 
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82 81' 83' 
Figure 58: Standard nomenclature for protease substrate cleavage. Pm P3, P2, Ph PI', P/, 
P3', Pn" designate the amino acid side chains of a peptide substrate. Cleavage occurs 
between the PI and PI' residues. The corresponding binding sites in the protease active-
site are designated as Sn, S3, S2, S], SI', S2', S3',Sn,.39 
The chemical nature of the protease S2 pocket, and in particular the amino acid 
residue 205 (papain numbering), is thought to be critical for substrate preference. 
Cathepsin B activity can be differentiated from the cathepsin L by hydrolysis of 
small peptides that contain arginine at P2 by cathepsin B. The cathepsin Band L 
subfamily can be further delineated by the length and sequence similarity within 
the respective pro-regions as well as the number and order of cysteine residues 
involved in disulfide bond formation. 36 
Cysteine proteases are recognized to be critical to the life cycle or pathogenicity of 
many parasites, such that they are promising targets for antiparasitic 
chemotherapy. They play important roles in immunoevasion, enzyme activation, 
virulence, tissue and cellular invasion, as well as excystment, hatching and 
moulting. Cysteine proteases are mechanistically similar to serine proteases, but 
they are better nUcleophiles, due to the extra shell of electrons present in the sulfur 
of the thiol group. The nucleophilicity of the thiol group is enhanced by the close 
proximity of an active site histidine which acts as a proton donor/general base.36,37 
Cysteine proteases are functionally diverse due to their unique nucleophilicity, 
adaptability to different substrates and stability in different biological 
environments. Parasitic cysteine proteases function in a broader chemical 
environment when compared to their homologous host enzymes. Mammalian 
lysosomal cysteine proteases are relatively unstable at neutral pH when compared 
to the parasite cysteine protease. The instability of mammalian cathepsins may be 
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cellular or tissue compartments. The lysosomal pH has been estimated to be as 
low as pH 4.0, and low pH can activate lysosomal enzymes as well as denature 
protein substrates. On the other hand parasite cathepsins are stable and active at 
low pH, in addition they remain stable and even more active at neutral pH.l6 
A peptide substrate or protein must bind to the protease's active site before the 
hydrolysis of the peptide bonds. The binding efficiency is a function of both the 
respective chemical environments that the protease subsites create, and the 
chemical nature of the peptide that interacts directly with the active site groove. 
Important factors affecting the interactions include; size, polarity, charge, 
hydrophobicity and acceptability. Although a single peptide bond is cleaved 
during catalysis, a number of amino acids on either side of the site of cleavage are 
critical to fix the catalytic register and specificity of an enzyme (figure SA). 
Sequences that directly flank the active site cysteine and histidine residues are also 
highly conserved to maintain the catalytic register.36 
The sulfhydryl or -SH group of the cysteine side chain and the imidazole of 
histidine give rise to a thiolate-imidazolium charge relay diad (figure SC). This is 
frequently but not always, stabilized by a highly conserved asparagine. A highly 
conserved glutamine forms the oxyanion, a crucial element in forming an 
electrophilic centre to stabilize the tetrahedral intermediate during hydrolysis. The 
two ionisable groups of the thiolate-imidazolium diad allow a broad pI-I range of 
enzymatic activity, consistent with a pKa of cysteine ~ 4.0 and pKa of histidine 
ionization ~ 8.S. The charge relay diad is stabilized by the chemical environment 
of the active site. It is thought that the main interactions of papain-like cysteine 















Figure 5C: Schematic representation of the active site showing: proximity of sulfhydryl 
of cysteine to the imidazole group of histidine, and the equilibrium with the thiolate-
imidazolium charge relay diad.36 
The mechanism of hydrolysis of the peptide bonds has been elucidated and 
documented (scheme 1). During peptide hydrolysis, the nucleophilic thiolate 
cysteine attacks the carbonyl carbon of the scissile amide bond of the bound 
substrate, and forms a tetrahedral intermediate which is stabilized by the so called 
oxyanion. The tetrahedral intermediate transforms into an acyl enzyme (enzyme 
substrate thiol ester) with the simultaneous release of the C-terminal portion of the 
substrate (acylation). This step is followed by the hydrolysis of the acyl enzyme 
with water, forming a second tetrahedral intermediate which finally splits into the 
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Scheme 1: Mechanism of substrate hydrolysis by cysteine proteases.37 
2.2. Malarial and Trypanosoma) cysteine proteases 
It is now clear that the malaria parasite has three cysteine proteases, falcipain-l, 
falcipain-2 and falcipain-3. Falcipain-l is not the most important contributor to 
hemoglobin degradation. Current evidence suggests that falcipain-l is involved in 
invasion of the host cell by the malaria parasite.4 The malarial cysteine proteases 
that playa critical role in hemoglobin degradation are falcipain-2 and falcipain-
3.36 Falcipain-2 and -3 are predominantly expressed in the merozoite acidic 
vacuole where hemoglobin hydrolysis occurS.38-40 Falcipain inhibitors that inhibit 
hemoglobin degradation also block parasite development. Thus faJcipain is 
considered a promising target for antimalarial chemotherapy. In actual fact, drug 
development should consider the inhibition offalcipain-2 and falcipain-3 in order 
16 
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to effectively inhibit parasite hemoglobin hydrolysis, and thus block parasite 
growth.41 
Trypanosoma cruzi, the causative agent of American trypanosomiasis (Chagas' 
disease) is transmitted to humans either by triatomine vectors or infected blood 
products. It is found as an intracellular form, the amastigote, and as a 
trypomastigote form in human blood. Chagas' disease affects primarily the heart 
and the nervous system. Presently available chemotherapy (nifurtimox, 
benznidazole) has limited potency and severe side eHects for the treatment of 
chronic forms of the disease. Efforts to characterize novel chemotherapeutic 
targets in T. cruzi identified a papain-like cysteine protease, called cruzain. 
Cruzain is found in all stages of the life cycle of T. cruzi. Inhibition of cruzain has 
been shown to impair in vitro cell invasion and to block amastigote replication as 
well as trypomastigote-amastigote differentiation, thereby arresting intracellular 
development. 37 
T. brucei rhodesiense is one of the causative agents of human African 
trypanosomiasis (sleeping sickness), which is transmitted by the bite of the tsetse 
ny. Infections with Tbrucei rhodesiense and other trypanosomes result in severe 
clinical consequences if left untreated. Clinical manifestations of African 
trypanosomiasis are intermittent fever, headaches, maniacal behavior, transient 
edema, and excessive sleepiness. Rhodesain is the major cysteine protease of T. 
brucei rhodesiense, and has been identified in all life-cycle stages of the parasite, 
especially during infection and parasite development. Inhibition of rhodesain by 
synthetic inhibitors has been shown to arrest T. brucei rhodesiense. This has 
further shown that rhodesain is important for the life cycle of the parasite.37 
2.3 Inhihition of cysteine proteases 
As alluded to earlier, cysteine proteases catalyze the hydrolysis of amide bonds in 
peptides and proteins through nucleophilic attack by the active site cysteine thiol 
on the amide carbonyl. This mechanism has been exploited by many cysteine 
protease inhibitors, which have an electrophilic moiety, such as a carbonyl or 
Michael acceptor moieties that react with the active-site cysteine residue.42 The 
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in almost all protozoan parasites, and also possess a highly reactive thiol group 
which is a target of the electrophilic moieties of the inhibitors developed.43,44 
Previously, it was not clear as to whether cysteine protease inhibitors could arrest 
parasitic infections without toxicity to the human host due to the fact that 
cathepsin Band L are major lysosomal proteases found in almost every cell in 
humans and domestic animals. Also, cathepsin S is another enzyme that is thought 
to playa role in peptide hydrolysis. Some inhibitors of cysteine proteases such as 
vinyl sui fones, are very effective inhibitors of parasitic cysteine proteases, and 
there was an initial concern about their toxicity towards the homologous host 
cathepsins B, Land S. However, to date no toxicity has been reported against the 
homologous host enzymes.45 There are possible explanations as to why these 
inhibitors are not toxic to the host enzymes. Firstly, the concentration of proteases 
like cathepsins B, Land S in mammalian cells may be considerably higher than in 
parasites. Secondly, mammalian cells have a much larger array of cysteine 
proteases, as well as other classes of proteases which may provide a level of 
d d c: d' . . 4445 I h re un ancy not loun In parasitic systems.' n any case, t ere are no 
autoimmune phenomena or laboratory and histologic abnormalities reported with 
some of the tested inhibitors. In addition, safety studies show little toxicity against 
the homologous host enzymes. 45 Studies have thus proved that cysteine protease 
inhibitors can selectively arrest parasite infections without undue toxicity to the 
host.44 
2.3.1 Classification of cysteine protease inhibitors 
A variety of cysteine protease inhibitors designed and synthesized thus far are 
divided into three mechanistically distinct groups, which are; 
(i) A series of active site titrants, whose mechanism of inhibition is based 
upon irreversible alkylation of the thiol moiety of the active site cysteine 
residue. The first specific irreversible inhibitors for proteases (serine, 
cysteine and threonine) were designed by attaching a reactive warhead to a 
good substrate structure. The early warheads used were alkylating agents 
such as diazo compounds or haloketones. Examples of irreversible 
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active site cysteine residue to form an irreversible thioether adduct. Their 
mechanism of inhibition is not fully resolved. However, it is generally 
agreed that there are two possible mechanisms of inhibition, one 
mechanism involves direct displacement of the halide group of the 
inhibitor by the thiolate anion of the cysteine residue to form a thoiether 
adduct (scheme 2a). While the other mechanism involves a thiohemiketal 
and a three-membered sulfonium intermediate. The intermediate then 
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Scheme 2a: Irreversible inhibition of cysteine protease by chloromethyl ketones: direct 
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Scheme 2b: Irreversible inhibition of cysteine protease by chloromethyl ketones: 
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Peptidyl diazomethyl ketones are also irreversible inhibitors of 
cysteine proteases, and they also alkylate the active site thiol group. 
Their mechanism of inhibition is thought to involve a proton transfer 
from the active site histidine (1m imidazole of histidine) residue to 
the methylene carbon of the inhibitor with thc loss ofN2 and alkylation 
of the active site cysteine residue. The other postulated mechanism 
involves addition of the cysteine residue to the carbonyl group of the 
inhibitor to give a tetrahedral adduct, which then rearranges to form an 
irreversible thioether adduct (scheme 3).46-48 
o 
----J ....... R~:~C=N=N 
~ ~ H 
+ -His- ---lmH 
Cys- - -His + -lmH 
+ 
Scheme 3: Irreversible inhibition of cysteine protease by diazomethyl ketones 
Peptide and amino acid derivatives that contain a Michael acceptor are 
specific irreversible inhibitors of cysteine proteases. This class includes the 
vinyl sulfones and a,~-unsaturated carbonyl derivatives.46-48 The 
mechanism of inhibition by vinyl sulfones and a,~-unsaturated esters and 
other a,~-unsaturated carbonyl derivatives involves a Michael addition. 
The active site cysteine residue attacks the ~-carbon , followed by the 
protonation of the a-carbon to form an irreversible thioether adduct 
(scheme 4). Irreversible inhibitors are also called alkylating agents because 
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Scheme -I: Irreversible inhibition of cysteine proteases by vinyl sulfones 
(ii) Another serIes of inhibitors fonns a covalent, yet reversible transition 
state-like intennediate with the active-site cysteine residue. Examples of 
this series include carbonyl based peptidyl aldehydes (scheme 5), ketones 
and a-keto esters and amides. Reversible inhibition usually involves the 
noncovalent interaction between the enzyme and the inhibitor. However, 
there are cases whereby covalently bound inhibitors result in reversible 
inhibition because of hydrolytically labile bonding. Some reversible 
inhibitors bind to the enzyme with high affinity, resulting in slow 
dissociation of the enzyme-inhibitor complex, such that they appear 
irreversible, thus they are therefore tenned tight-binding reversible 
inhibitors. There are also some reversible inhibitors that inhibit the 
cysteine protease very slowly due to confonnational changes following 
enzyme-inhibitor complex fonnation, and these are tenned slow-binding 
reversible inhibitors. Peptidyl semicarbazones represent an example of 
reversible inhibitors. They have been used previously as intennediates for 
the synthesis of peptidyl aldehydes, which are also reversible inhibitors.48 
Their mechanism of action involves the fonnation of a reversible 
tetrahedral adduct. The cysteine residue thiolate anion attacks the protected 
carbonyl carbon (C-5 carbon, scheme 6a).44,48,49 Another group of 
reversible inhibitors that are structurally related to semicarbazones are the 
thiosemicarbazones. Their mechanism of inhibition involves attack of the 
thiocarbonyl carbon (C=S) of the inhibitor by the thiolate anion of the 
cysteine residue (scheme 6b). They are non-peptidic and are better 
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Scheme 6a: Reversible inhibition of cysteine proteases by peptidyl semicarbazones 
Scheme 6b: Reversible inhibition of cysteine proteases by thiosemicarbazones 
(iii) The last series of inhibitors fonns a stable thioacyl-enzyme complex with 
the active site cysteine which, by nature of this intennediate is slow to 
hydrolyze. Thus, they are called slow turnover inhibitors, and examples of 
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Carbazate ester (15) 
Figure 6: Examples of slow turnover inhibitors 
2.4 Inbibitors of malarial and trypanosomal cysteine proteases 
Extensive research to identify newer targets for chemotherapy has led to the 
identification of protease inhibitors as an attractive alternative. The disruption of 
the hemoglobin degradation in the malaria parasite seems to be a logical approach 
to antimalarial chemotherapy. It has been demonstrated previously that 
fluoromethyl ketone-derivatized dipeptides could cure a murine infection of 
malaria.50 Then vinyl sulfone-derivatized dipeptides were also shown to be potent 
against the murine models of malaria.51 They were reported to potently block 
hemoglobin degradation and parasite grow1h in malaria.41 Several independent 
studies have confirmed the efficacy of vinyl sulfone-derivatized dipeptides to 
rescue mice from an acute lethal infection of T. cruzi.52 Preliminary studies have 
also confirmed that cysteine protease inhibitors can arrest the replication of T. 
brucei in mice.44 Vinyl sulfones, peptidyl chloromethyl ketones, diazomethyl 
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Diazomethyl ketone 
Vinyl sulfone Chloromethyl ketone 
Figure 7: Examples of irreversible inhibitors of cysteine proteases 
Chalcones have also been extensively studied against the malarial cysteine 
protease, falcipain. For example chalcone 17 (figure 7) was reported to have IC50 
values of 0.51 and 0.72 JlM against chloroquine resistant and chloroquine 
sensitive P. falciparum respectively.53 Acyl hydrazones and a,~-unsaturated 
amides exemplified by compound 18 are also reversible inhibitors of cysteine 
proteases. lsatins, are also well known reversible inhibitors of cysteine proteases54, 
and these as well as their thiosemicarbazone derivatives 19 have been shown to 
inhibit cruzain, falcipain-2, and rhodesain.55 Another class of compounds that 
have been evaluated against cruzain and rhodesain are the aryl ureas, represented 
by compound 20 that were found to be a promising class of compounds with 
acceptable IC50 values.
56 Lately, thiosemicarbazone derivatives represented by the 
general scaffold 21 (X = CH, N) have also been identified as inhibitors of cysteine 
proteases; cruzain, falcipain-2 and rhodesain. 57 A recent review has summarized a 
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Chalcone (17) Oxalic bis[(2-hydroxy-1-naphthalylmethylene)Jhydrazide (18) 
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X = CH, N 
Isatin thiosemicarbazone (19) 
Aryl urea (20) Thiosemicarbazone (21) 
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CHAPTER 3 
SYNTHESIS AND CHARACTERIZATION OF TARGET COMPOUNDS 
3.1 QUINOLINE THIOSEMICARBAZONES 
3.1.1 BACKGROUND AND RATIONALE 
3.1.1.1 Background on Quinoline compounds 
Recent efforts aimed at circumventing chloroquine and general aminoquinoline 
resistance have focused mainly on structure-activity relationship (SAR) studies of 
chloroquine and related 4-aminoquinolines. These studies included the removal of 
the 7-CI group, which abolished anti pI asmodi al activity. Thus it was then 
established that the 7-CI is important for chloroquine activity, even though its 
specific role is not fully understood. 59 Further studies included the substitution of 
the 7-CI group with various substituents such as F, Br, I, CF3 and OMe. 7-Iodo-
and 7-bromo-aminoquinolines (AQs) with short side chains werc generally active 
against both chloroquine-susceptible and chloroquine-resistant P. Jalciparum. In 
addition, 7-iodo-AQs with long (10-12 carbons) diaminoalkane side chains were 
also found to be active against both strains of P.Jalciparum. On the other hand, 7-
fluoro-AQs and 7-trifluoromethyl-AQs were generally less active than 7-Cl, 7-1, 
and 7-Br-AQs against both strains of P. falciparum. 7-0Me-AQs were inactive 
against both strains of P. falciparum. 59 
Further SAR studies included substitutions on other positions of the 
aminoquinoline rings, which resulted in reduced antiplasmodial activity. The 
length of the diaminoalkane side chain was also varied in order to investigate the 
effect it might have on the anti plasmodial activity. It was then observed that 
aminoquinoline derivatives with short (2-3 carbons) and long (10-12 carbons) 
diaminoalkane side chains were active against both chloroquine-susceptible and 
chloroquine-resistant strains of P. falciparum. On the other hand, aminoquinolines 
with intermediate (4-8 carbons) diaminoalkane side chains were only active 
against chloroquine-susceptible P. Jalciparum, but not active against chloroquine-
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SAR studies carried out by Egan et al. on chloroquine and related aminoquinolines 
suggest the following; 61 
(i) Chloroquine and related antimalarial drugs act by complexing 
ferriprotoporphyrin IX (Fe(III)PPIX), inhibiting its conversion to ~­
hematin (hemozoin) and hence its detoxification. 
(ii) The basic amino side chain is also essential for antiplasmodial activity and 
drug accumulation in the food vacuole of the P.falciparum. 
(iii) The presence of the 7-chloro group in the 4-aminoquinoline ring is 
required for ~-hematin inhibition. 
Hence these studies suggest that there is still merit in pursuing quinolines for 
antimalarial activity. These SAR studies are summarized in figure 9 below. 
r-... ------~ 




'I' Weak bases: assist in 
drug accumulation 
via pH trapping 
Figure 9: Proposed structure-activity relationship studies in chloroquine 
3.1.1.2 Background on Thiosemicarbazones 
Thiosemicarbazones are a class of compounds possessing a wide spectrum of 
medicinal properties. They have been studied and evaluated among other diseases, 
. b I' 62 d . . 63 II . h . 64 agamst tu ercu OSIS ,an trypanosomIasIs ,as we as anticancer t erapeutlcs , 
as well as for their parasiticidal activity against Plasmodium jalciparum.65 
Currently, a thiosemicarbazone, Triapine, is being evaluated in human phase II 
trials as an antineoplastic therapeutic.66 
Recently Du and coworkers49 reported a series of thiosemicarbazones possessing 
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Another series of thiosemicarbazones based on the isatin scaffold was reported by 
Chiyanzu and coworkers55• Inhibitory activity against cruzain, falcipain-2 and 
rhodesain was studied and promising scaffolds identified. Thus based on these 
reports, thiosemicarbazones represent a promising class of compounds on which 
to base antiprotozoal cysteine protease inhibitors. 
Work by Du and coworkers49 on thiosemicarbazones generated the basic 
structure-activity relationships (SAR) against cruzain. This SAR is summarized in 
figure 10. Firstly, the authors examined the nature of halide substituents on the 
aromatic ring, which were tolerated. Secondly, the variation of an alkyl group (R") 
at position 5 of the thiosemicarbazone scaffold was studied, and the trend of 
activity was observed to increase with the size of the substituent; H < methyl < 
ethyl. Thirdly, substitution at the Nt nitrogen was evaluated, with 
monosubstitution on the Nt nitrogen, resulting in reduced activity. Fourthly, the 
effeet of sulfur in the C=S double bond was also investigated by substitution of 
sulfur with oxygen, and this resulted in poor activity of the compounds, leading to 
the conclusion that sulfur is important for activity. This led the authors to 
conclude that the logical site of attack by the active site's cysteine thiol is the 
double bond. Lastly the C=N4 double bond was reduced to a C-N4 single bond 
resulting in poor activity. 
Similar studies were carried out by Klayman and coworkers65, in this case for 
antimalarial activity. With regard to the C=S double bond it was found that the 
sulfur is indeed critical for the activity of the compounds, as the c=o double bond 
diminished antimalarial activity. In addition, structure-activity relationship studies 
with regard to substitution at the N I nitrogen were carried out with a variety of 
substituents. It was observed that Nl-disubstitution by both alkyl groups resulted 
in varying activities. For example the NI,NI-diethyl compound showed no 
antimalarial activity in vitro. On the other hand, an NI,NI-disubstitution with a 
methyl and a cycloalkyl group resulted in cures in vivo at dosages of 80-320 
mg/kg, and higher doses resulted in toxicities. Compounds with N I-nitrogen atom 
incorporated into 4-9-membered rings were also evaluated in this study, and 
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Synthesis and Char(:icterization 
Reduction to single 
bond reduces potency 
Figure 10: Summary of Known Thiosemicarbazone Structure Activity Relationship 
Studies with Cruzain49 
Recent studies carried by Greenbaum and coworkers57 on thiosemicarbazones 
against the parasitic cysteine proteases; cruzain, falcipain-2 and rhodesain 
revealed that substituents at the 3' or 4' position on the aryl ring are most favored 
to bind protease targets and therefore merit expansion. On the other hand, the 
parasite SAR studies revealed that the pyridine thiosemicarbazones do not inhibit 
the target cysteine proteases, but are excellent parasiticidal compounds, especially 
compounds 22 and 23. Furthermore compounds 24, 25 and 26 were shown to be 
effective against both T. brucei in culture and rhodesain, and this is the only case 
where enzyme inhibition was also matched with parasiticidal activity in culture. 
Lastly, N I NH2-substitution lowered the potency against the target proteases, but 
enhanced killing of T. brucei and P. /alciparum, especially in compounds with a 
protonatable terminal nitrogen like compound 27. The authors suggest that this 
may be due to the increased uptake of the compound across cell membranes or 
enhanced binding to another target protein. 
Other scaffolds were also discovered during this study, which represent more 
general parasiticidal compounds capable of killing all parasites. Two of the 
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S atoms), while two scaffolds 22 and 23 are potential tridentate metal chelators. 
Their mechanism of action is not very clear, but it seems that compounds 27 and 
28 can inhibit proteases, although 28 only inhibits rhodesain, while 27 inhibits 
rhodesain and cruzain. Yet both 27 and 28 can kill the organisms. On the other 
hand compounds 22 and 23 do not inhibit the target proteases, but are very 









Figure 11: Structures of thiosemicarbazone scaffolds with activity against multiple 
. d' 57 cysteine proteases an parasites. 
The detailed mechanism of action of thiosemicarbazones has not been clear. The 
antimalarial 2-acetylpyridine thiosemicarbazones may be acting as tridentate iron 
chelators in P. falcipanlm. There are two known ways for metal chelators to 
inhibit growth of P. falcipantm: withholding iron from plasmodial metabolic 
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3.1.1.3 Rationale on Quinoline thiosernicarbazones 
In view of the background presented in sections 3.1.1.1 and 3.1.1.2 above, we 
decided to design and synthesize quinoline thiosemicarbazones primarily directed 
at Plasmodium Jalciparum. The rationale in this regard is based on a multi-
therapeutic strategy summarized in figure 12. It is noteworthy that compounds 
such as thiosemicarbazones with multiple mechanisms of action could be useful in 
slowing down the emergence of antimalarial drug resistance or even overcoming 
it. Compounds aimed at a single target are more likely to be rendered ineffective 
due to the emergence of resistant parasites compared to compounds aimed at 
mUltiple targets. 
Initially a strategy was envisaged in which the thiosemicarbazone moiety might 
inhibit the cysteine proteases via multiple mechanisms, while the quinoline 
nitrogen along with the thiosemicarbazone hydrazinic nitrogen would be 
important for accumulation in the acidic food vacuole of the parasite. In addition, 
metal chelation involving the sulfur of the thiocarbonyl (C=S) group and the N4 
hydrazinic nitrogen atom of the C=N double bond was envisaged. Inhibition of 
some metalloenzymes such as falcilysin was also envisaged by the 
aforementioned metal chelation property of the thiosemicarbazone moiety. Metal 
chelation was envisaged for the iron in the red blood cells, because many enzymes 
in the malaria parasite in the el)1hrocytes depend on iron. Therefore it can be 
inferred that if iron can be withheld from the parasite by the iron chelating 
thiosemicarbazone moiety, this may disrupt the metabolism of the parasite by, for 
example preventing DNA synthesis (through the inhibition of the iron-dependent 
enzyme. ribonucleotide reductase), inhibiting de novo synthesis of heme and 
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Figure 12: Envisaged Multitherapeutic strategy of quinoline thiosemicarbazones against 
Plasmodium Jalciparum. 
Several classes of iron-chelating compounds have been reported to inhibit the 
growth of P. falciparom in the red blood cells. Numerous studies indicate that the 
degree of antimalarial activity of iron chelators correlates with the degree of 
lipophilicity, or the ability to cross the cell membranes, of the compounds.69-n The 
antimalarial iron chelators can be categorized based on the predominant 
mechanism of inhibition of parasite growth. There are two categories; those that 
withhold the iron from the plasmodial metabolic pathways, or those that form 
toxic complexes with iron.69 
The mechanism of antimalarial activity of Fe(III) chelators appears to be 
sequestration of iron necessary for plasmodial replication. On the other hand, 
Fe(II) chelators seem to have an antiparasitic effect other than the withholding of 
iron. An example of an Fe(lI) chelator is the aromatic 8-hydroxyquinoline, which 
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blood cells to produce a rapidly lethal free-radical-mediated intracellular 
reaction.68,73 
We also envisaged that the thiosemicarbazones could inhibit the target cysteine 
proteases by two independent mechanisms that utilize two unique chemistries of 
the active site cysteine thiol namely; nucleophilicity and metal binding properties. 
With regard to nuc]eophilicity, we envisaged alkylation of the active site thiot via 
addition to either the imine C=N double bond or the C=S of the thiol carbonyl 
group (Scheme 7). Regarding metal binding properties of the active site thiol, we 
reasoned that thiosemicarbazones might be metal-interactive inhibitors of cysteine 
proteases upon intracellular formation of a metal complex to which the active site 
thiol could coordinate. This metal-interactive inhibition of a cysteine protease has 
recently been demonstrated for metal chelating biguanides.74 Various biguanides 
were reported to be metal-interactive inhibitors of cathepsin B from mammals and 
falcipain-2 from P. Jalciparum. Before this disclosure, antimalarial and 
antidiabetic biguanides had been unrecognized cysteine protease inhibitors, 
revealing protease inhibition as a contributing therapeutic mechanism in both 
diseases. Some biguanide derivatives might co-bind metals such as Zn2+. Cu2+ and 
Fe2-, and substrate recognition sites so as to enhance the natural inhibitory action 
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Scheme 7: The proposed mechanism of action of thiosemicarbazones against cysteine 
proteases from Plasmodiumfalciparum. 
3.1.1.4 Synthesis and Characterization 
General synthesis and characterization of (thio)semicarbazones 
A range of thiosemicarbazones and semicarbazones were synthesized by the 
simple treatment of appropriate aromatic aldehydes or aromatic methyl ketones 
with a thiosemicarbazide or semicarbazide in alcoholic solvents such as; 
methanol, ethanol or isopropanol under reflux (Scheme 8). A minimum amount of 
acetic acid (1%) was used in the case of methyl ketones.65 Reaction times varied 
between three hours for aldehydes and up to 24 hours for methyl ketones. The 
product yields were usually moderate to good. Work-up of the reaction mixtures 
was not necessary as the products usually precipitated out of the reaction solution. 
The corresponding structures of the products were readily characterized with the 
following spectroscopic techniques; IH-NMR, 13C_NMR, MS, IR spectroscopy 
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1/ './ Y 
R 
Ar Aromatic ring; R = H, Methyl; X = S, 0 and Y NHz, SCH}, NRR' 
Scheme 8: General synthesis of (Thio )semicarbazones 
Mechanism of the reaction 
The nucleophilic thiosemicarbazide (or semicarbazide) attacks the electrophilic 
carbonyl group of the aromatic aldehyde (or ketone) to produce intermediate II, 
from which iminium ion (in case of ketones) [II is formed, and eventually the 
product after loss of a proton from III. For ketone reactions, the added acid 
catalyzes the reaction by first protonating the carbonyl oxygen to generate 
intermediate IV. The proton lost from intermediate IV is used to convert the 
hydroxyl (OH) group in intermediate V into a good leaving group (water 
molecule) whose elimination from intermediate VI generates iminium ion m. It is 
noteworthy that the steps involved are reversible (scheme 9). 
V: R = Me 
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Syntbesis and cbaracterization of specific target (tbio)semicarbazones 
(Thio)semicarbazones 38-48 were prepared from the treatment of 
quinolinecarboxaldehydes 29-34 with scaffolds 35-37 (scheme 10). N,N-
Disubstituted and N-monosubstituted derivatives 49-53 were synthesized by 
reaction of thiosemicarbazone thioesters 41 and 43 with selected primary and 
secondary amines (scheme 11). The selected amines were piperidine, 3-
dimethylamino-l-propylamine, and N' -(7-chloroquinolin-4-yl)-propane-1 ,3-
diamine. The reactions were carried out in methanol under reflux with a minimum 
amount of a co-solvent (THF) as the thiosemicarbazone thioesters 41 and 43 were 
insoluble in methanol. 
+ 
29-34 
R = H, 6-Me, 8-Me, 6-0Me 





H2N 'NAy .--.~ 
H 
x = S, Y = NH2, 35 
X = 0, Y = NH2, 36 
X = S, Y = SCH3, 37 
32: 2-chloro-6-methoxy-3-quinolinecarboxaldehyde 
















Scheme II: Reagents and conditions: MeOH (THF, co solvent). reflux 12 hrs 
H 
For structure-activity relationship studies, only two acetylquinolines were 
synthesized and converted into (thio)semicarbazones. First, the 2-
quinolinecarboxaldehyde 30 was converted to 2-acetylquinoline 55 via a two step 











Chapter 3 __ _ ____________ ---"'S.,.Ly.:..:.nt:::-'.h=esis and Characterization 
30 to form intermediate 54, followed by oxidation using the modified Moffat 
oxidation protocol of sulfur trioxide. pyridine complex (scheme 12).75-77 The 
product yields for the intermediate 54 and 2-acetylquinoline 55 were 58 % and 99 
% respectively. For the synthesis of 8-acetylquinoline 58, commercially available 
8-hydroxyquinoline 56 was transformed into triflate 57 by reaction with trifluoro-
methanesulfonic anhydride in the presence of pyridine (base and solvent). The 
reaction proceeded in 87 % yield. Triflate 57 was then coupled to butyl vinyl ether 
using the Heck reaction catalyzed by palladium (0) to give 8-acetylquinoline 58 
after acid hydrolysis in 86 % yield (scheme 13).78.79 Both of these acetylquinolines 
55 and 58 were treated with thiosemicarbazide 35 and semicarbazide 36 to yield 
the desired thiosemicarbazones or semicarbazones 59-62 (Scheme 14, table I). 
30 
54 55 
Scheme 12: Reagents and conditions: (i) MeMgBr (2.0 equiv.), THF, 58%; Oi) Et3N (5.0 




Scheme 13: Reagents and conditions: (i) Pyridine, Trifluoromethanesulfonic anhydride 
(1.10 equiv.). 87%; (ii) Pd(OAc)2 (0.05 equiv.), dppp (0.055 equiv.), Et3N (3.0 equiv.), 
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61; x = s 
62; X= 0 
Scheme 14: Reagents and conditions: EtOH, Acetic acid (1 %), reflux, 24 hrs. 
The Heck Reaction8o,81 
This is one of the reactions in organic chemistry based on transition metals. The 
Heck reaction is one of the most synthetically useful palladium-catalyzed 
reactions. It couples together an alkene with a halide or triflate to form a new 
alkene. Catalytic palladium Pd(O) is needed for this reaction (scheme 15). The 
method is very efficient, and carries out a transformation that is difficult by more 
traditional techniques. The alkene can be mono- or disubstituted and can be 
electron-rich, poor or neutral. The base need not be at all strong and can be Et3N, 
NaOAc or aqueous Na2C03. 
+ 
Pd(O) catalyst .... 
Base 
R 1 :::: Aryl, vinyl, alkyl without beta-H's on an Sp3 carbon 
X :::: halide, triflate 
Scheme 15: The Heck reaction 
The mechanism of the reaction involves oxidative addition of the hal ide or triflate, 
insertion of the olefin, and elimination of the product by a ~-hydride elimination 
process. A base then generates the palladium (0) catalyst. The whole process is a 
















R 1~ 2 Beta-hydride 
R elimination 
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1 H-NMR spectroscopic evidence for the confirmation of the structure of the 
intermediate alcohol 54 from 2-quinolinecarboxaldehyde 30 was observed by the 
disappearance of the aldehyde (CHO) proton, which appears in the region 9.89-
10.3 ppm. This proton is replaced by methyl (CH3) protons, which appear as a 
doublet at 1.58 ppm and hydrogen on the adjacent carbon, which appears as a 
quartet at 5.04 ppm. The methyl (CH3) protons and the hydrogen at 1.58 and 5.04 
ppm respectively, disappear and were replaced by a singlet for COCH3 at 2.86 
ppm to confirm the structure of the methyl ketone 55. Similar 1 H-NMR 
spectroscopic evidence was observed for 8-acetylquinoline 58, with the COCH3 
protons appearing as a singlet at 2.94 ppm. 
All the (thio)semicarbazones were obtained as powders with different colours. The 
synthetic yields for the products ranged from very low (8 % for 53 and 22 % for 
50, Table I) to very high (87 % for 39 and 41 and 92 % for 43, Table I), however 
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NI'-substituted thiosemicarbazones 49-53 were low to moderate (Table 1). This 
could be partly due to the poor solubility of the starting material in methanol 
which required the use of a co-solvent. Column chromatography was used to 








Table 1: First series of (thio)semicarbazones synthesized with their respective yields 
and melting points. 
i ~;Pd i:· I :H2 i ~ ( ( i ~~Yield I :~~ 
I. 39 Is· I' SCH3 1- ! - I'. - 1 87 i~:~-! 
I I' .! J 85 I 
ro-i iNH2 --:- 1- i- 1:78 !~::~ 
41 I S I· SCH3---lI.-H--l-i ·-·--r--+87 197· 
: ! I 1 199 
, I I I . 
I NH, : H , - 1- i 77 I ~:~-
r3 liS I SCH3 ~ - H I H i 92 I' 208- I 
I ~ I I r 1 NH, 1- !6-0Me 1c1 ! 71 i ~~~- I 
F~+-I o::----iII-:-N-:c:-cH-2 --+1---+1 6--~ .. 76 7.' ~::~:-i 
: 
I 1 nne 1 C'! , 267 
S i NH2 1- \ 6-Me 1 CI ! 74 .. ~.ino=-i 
I I I I ~2' r7 10 I NIl, 1- : 6-Me 1 CI 144 --I ~:1 






















S !NH(CH2hNMe2 H - - 55 195-
197 
S HN NH H - - 22 209-
CI N 212 
S N 
J 
- H H 57 174-
176 
S !NH(CH2hNMe2 - H H 63 195-
198 
S HN NH - H H 8 209-
CI N 212 
S NH2 CH3 - - 40 160-
162 
0 NH2 CH3 - - 48 228-
232 
S - - - - 44 208-
211 
0 - - - - 48 177-
179 
lH-NMR spectroscopic evidence for the confirmation of the structures of 
(thio)semicarbazones from aldehydes was observed by the disappearance of the 
aldehyde (CHO) proton which appears as a singlet in the region 9.89-10.3 ppm. 
This is replaced by the imine (HC=N) proton which is observed as a singlet 
around 8.2-8.9 ppm. The other noticeable observation in the lH-NMR spectra is 
the secondary NH proton of the (thio)semicarbazone moiety in the region around 
11.7 ppm. The thiosemicarbazone thioester has a singlet for the SCH3 protons in 
the region 2.53-2.73 ppm. The methyl (CH3) protons of the methyl ketone around 
2.86-2.94 ppm, shift slightly upfield to the region 2.35-2.59 ppm when the methyl 
ketone is incorporated into the thiosem icarbazone scaffold. Further evidence for 
the confirmation of the products is also observed in the 13C_NMR spectra. The 
thiocarbonyl carbon of the thiosemicarbazone (S=C-NH2) is observed at about 180 
ppm. On the other hand the thiocarbonyl carbon for the thiosemicarbazone 











Chapter 3 Synthesis and Characterization 
NNH 
the semicarbazone (O=C-NH2) chemical shift is observed at about 157 ppm. The 
NH peak observed in the region 3000-3500 cm-J in the IR spectra was also 
evidence that the (thio)semicarbazones had been formed. The HRMS data of the 
derived compounds indicated the molecular ion peak corresponding to the 
molecular formulae of the compounds. The elemental analyses of the 
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3.2. CHALCONES AND PYRAZOLINES 
3.2.1. BACKGROUND AND RATIONALE 
3.2.1.1. Backgrouud on Chalcoue derivatives 
Synthesis and Characterization 
Chalcones are a,~-unsaturated ketones (figure 14). Chalcones have demonstrated 
preferential reactivity towards thiols in contrast to amino and hydroxyl groups. 
This has implications in tenns of eliminating problems of mutagenecity and 
carcinogenicity which would result from interactions with nucleic acids.82 They 
are a structurally simple group of compounds that have displayed an impressive 
range of phannacological activities; among which includes antiprotozoaI83-85, anti-
inflammatory86, immunomodulatory87, nitric oxide inhibition88 and anticancer 
activities89. Chalcones that combine a wide range of activities may be 
advantageous or disadvantageous. A combination of phannacological activities 
can enhance the likelihood of undesirable side effects. On the other hand, it may 
be advantageous for dual-acting drug development, especially if related activities 
(for example, antiprotozoal) are involved.89 
Reports on chalcones that combine activities against a number of protozoal 
infections are rare. However, there are reports about licochalcone A, a natural 
chalcone derivative isolated from Chinese licorice roots, and other chaIcones 
which possess both antileishmanial and antimalarial activities. 83,90-92 This shows 
that the combination of activities is not an unreasonable expectation for this class 
of compounds. Within the context of antimalarial cysteine protease inhibitors, Li 
and coworkers83 have reported a series of chalcones that were evaluated against 
both the sensitive and resistant strains of P. falciparum. The observed resistant 
indexes for the series of chalcones were substantially lower than that of 
chloroquine, thus suggesting that their mechanism of action is different from that 
of chloroquine. It was suggested that chaIcones inhibit malarial cysteine protease 
via a Michael addition type of reaction, by binding to the nucleophilic side chain 
ofthe enzyme.83 
Chalcones have similarities with acyl hydrazides. They roughly have the same 
overall size, and they also have aromatic rings at both ends of the chain linker. It 
was suggested that both the chalcones and acyl hydrazides (figure 14) could 
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adopt similar binding modes. However, since the inhibition of the malarial 
cysteine protease occurs inside the acidic food vacuole of the malaria parasite, the 
relative acid stability of the a,p-unsaturated ketone linker of chalcones offers an 
advantage over the more potentially labile hydrazide linker in the acyl 
hydrazides.83•93,94 Such an effect could be partly responsible for the observed 
higher potency of chalcones relative to the corresponding acyl hydrazides. In 
addition, the a,~-unsaturated ketone linker provides conjugation between aromatic 
groups at both ends of the linker. Furthermore, the presence of the a,~-unsaturated 
ketone linker has been shown to be critical for activity, as reduction to the 
saturated linker resulted in lower potencies against the malaria parasite.83 
The DOCK program and modeling studies further suggest that chalcones adopt a 
more extended conformation, due to the conjugated linker. Therefore, this 
generates a linear, almost planar structure which fits well into the long cleft of the 
active site of the malarial cysteine protease. On the other hand the saturated 
ketone counterpart would be expected to adopt less extended conformation 
because of the two Sp3 hybridized carbons in the linker, thereby giving rise to less 
favorable interactions with the protease.83 
It has been suggested that chalcones with a quinoline ring attached to the p-carbon 
of the a,p-unsaturated linker have enhanced antimalarial activity due to the 
following reasons: 83 
(i) Protonation of the nitrogen atom in the quinoline ring under weakly acidic 
conditions may enhance their interactions with the protease at His67 in the 
active site, or else protonated His67 may form a hydrogen-bond with the 
inhibitors. 
(ii) The quinolines may be somewhat concentrated inside the malarial acidic 
food vacuole (pH ~ 5), i.e. they have enhanced accumulation into the food 
vacuole. 
"R 
Chalcones Acyl hydrazides 











Chapter 3 _______________ S~, YJ-'n=t=he~is and Characterization 
3.2.1.2 Background on Pyrazoline derivatives 
Pyrazoline derivatives have been reported to have activity against a wide range of 
therapeutic targets.9S-IOI Pyrazoline derivatives of thiosemicarbazones have been 
studied recently in an effort to investigate the influence of restricted molecular 
flexibility in the activity of the compounds against cruzain and T. crnzi.
49 
Molecular flexibility is a property that has not received much attention in the 
study ofbioactive molecules as therapeutic agents. In addition; oral bioavailability 
is also an important factor to consider in the development of therapeutic agents. 
Thus an important goal for therapeutic research, is sufficient knowledge and 
understanding of the molecular properties that limit oral bioavailability.102 Factors 
that have been considered as a primary guide to correlating physical properties 
with successful drug development by previous researchers are; lipophilicity, 
molecular weight (MW < 500), and the number of hydrogen bond donors and 
acceptors.I02-104 However, one of the properties, namely molecular flexibility has 
not received much attention, and it is postulated to be important for membrane 
permeation.102,IOS Membrane permeation in return is important for oral 
bioavailability in the absence of active transport, and failure to achieve this 
usually results in poor oral bioavailability. Studies on molecular flexibility suggest 
that molecular rigidity plays a pivotal role in blocking out access to the clearance 
enzymes; while the activity against the target in not compromised.102 
3.2.1.3 Rationale for Pyrazoline derivatives as Potential Antimalarial agents 
We have thus reasoned that pyrazoline derivatives are an interesting class of 
compounds due to their activity against a wide range of therapeutic targets on the 
basis of the aforementioned background (3.2.1.2). Thus our rationale is three-fold 
(partly summarized in figure IS): 
• A comparative study of antimalarial activity of chalcones and 
corresponding pyrazolines has to date not been carried out. We wished to 
conduct a preliminary study in this regard. 
• We reasoned that the presence of the two nitrogen atoms in the pyrazoline 
ring could lead to increased accumulation of the compounds in the acidic 
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• The NH group in pyrazoline provides a nucleophilic site for introducing 
further chemical diversity by reacting with a wide range of readily 
available electrophilic building blocks such as acid chlorides, isocyanates 
and sulfonyl isocyanates. This would facilitate SAR studies. 
In this regard sulfonyl ureas were rationally targeted because they are known 
to possess some antimalarial activity by blocking permeation pathways.106 
• Introduction of 
I chemical diversity 
Figure 15: Envisaged structure-activity relationships of Pyrazoline derivatives 
3.2.1.4 Synthesis and characterization 
General synthesis and characterization of precursor chalcones 
The synthesis of chalcone derivatives is based on a simple procedure, the Claisen-
Schmidt condensation reaction. A substituted aldehyde and an aromatic methyl 
ketone are condensed under base-catalyzed (NaOH or NaOMe) conditions, in 
methanol or ethanol at room temperature (Scheme 17).83,90 Co-solvents were used 
in cases where the starting materials are insoluble in methanol or ethanol. A 
minimum amount of methanol or ethanol must be used to ensure formation of a 
solid product, and the products are usually obtained as yellow precipitates. The 
corresponding structures of the products were readily characterized with the 
following spectroscopic techniques; I H-NMR, 13C-NMR, MS, IR spectroscopy 
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o 
Ii 
H + ~~. 
l~-R' 
Scheme 17: Reagents and conditions: NaOH or NaOMe; MeOH or EtOH; RT; 24hrs 
Mechanism of reaction 
The mechanism involves base-mediated enolization of the methyl ketone followed by 
reaction of the resulting enolate with the aldehyde in a classical aldol reaction. The 
resulting ~-hydroxy ketone then undergoes a base-mediated elimination to deliver the 
chalcone. The driving force for this elimination is the formation of a more stable 
conjugated chalcone system (Scheme 18). 








Synthesis and characterization of target chalcone analogues 
The chalcone analogues 66 and 67 were prepared from the Claisen-Schmidt 
condensation reaction using the quinolinecarboxaldehydes 63 and 64 with 2,4-
dichloroacetophenone 65 using sodium methoxide as a base in methanol at room 
temperature (Scheme 19). The formation of the product was observed immediately 
after the addition of sodium methoxide to the stirred solution of aldehyde and methyl 
ketone, however the reactions took 24 hours to go to completion. The chalcone 
analogues 66 and 67 were obtained in 85 % and 87 % respectively. 
RT(~~yyCHO + 
~N~CI 
R = OCH3• 63 
R = CH3 , 64 
R 
65 R = OCH3 , 66 
R = CHs. 67 
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The I H-NMR spectra confirmed the structures of the products. A noticeable change 
from the starting materials is the disappearance of the aldehyde and methyl ketone 
chemical shifts, which appear as singlets around 9.89-10.3 ppm and 2.5 ppm 
respectively. These protons are replaced by the a,p-unsaturated ketone linker protons 
observed as doublets in the region of 7.2-8.1 ppm with coupling constants of 16 Hz. It 
is evident from these coupling constants that the products formed are predominantly 
the trans-isomers (E-form). The rest of the protons appear in their expected regions 
with their usual coupling constants. Additional support for the structures of the 
chalcones comes from the I3C-NMR spectra, where the carbonyl carbon (C=O) of the 
a, p-unsaturated ketone linker is observed in the region 191 ppm, compared to the 
aldehyde carbonyl group (C=O) at 195 ppm and methyl ketone carbonyl group (C=O) 
which appears in the region 179 ppm. Their molecular weights are confirmed by the 
molecular ions observed in the mass spectra. 
Synthesis and characterization of target Pyrazoline derivatives 
The chalcone analogues 66 and 67 were treated with hydrazine hydrate in ethanol 
under reflux, to obtain the pyrazoline products 68 and 69 as white powders in 54 % 
and 83 % yields respectively. The resulting pyrazolines 68 and 69 were then 
condensed with substituted aromatic sulfonyl isocyanates 70-74 in THF at room 
temperature to produce a class of N-substituted pyrazole sulfonyl ureas 75-84 as white 
powders in moderate to good yields as well.94-96 The yields for compounds 75, 78, and 
83 were very low, and this could be partly due to the partial self-condensation of the 
aromatic sulfonyl isocyanates. This postulated self·condensation involves 
decomposition of the corresponding sulfonyl isocyanate to the corresponding 
sulfonamide via loss of CO2 in the presence of water, if the conditions are not strictly 
anhydrous. The resulting primary sulfonamide could then react with another molecule 
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R = OCH3, 66 
R = CH3 , 67 
R::: OCH3, 68 
R = CH3 , 69 
* chiral centre (ii) 
R2 = R3 = H, 70 
R2::: Me, R3::: H, 71 
R2 = H, R3 Me, 72 
R2 = H, R3::: CI, 73 
R2 = H, R3 = F, 74 
Scheme 20: Reagents and conditions: (i) EtOH, reflux, 12 hrs; Oi) THF, RT, 3hrs 
Table 5: Chalcones and Pyrazoline derivatives with their respective yields and 
I . . me tmg pomts 
Cmpd R RL RJ %Yield ! mp (0C) 
75 OCH3 H H 138 i 229-230 
\-----
1217=220 i 76 CH3 ·H H 57 
77 OCH3 CH3 H 85 ! 213-215 
78 CH3 i CH3 H 12 1213-214 
i 79 .OCH3 H CH 3 57 i 219-222 
80 CH3 H Cl-h 64 i 217-219 
• 
81 OCH3 i H 
I 
CI • 60 1235-236 
• 82 i CH3 H CI 52 
I 
233-234 _ .... 
83 OCH3 .H F 9 · i26-227 
. 
84 CH3 H F 74 1219-221 
_. 
The 1 H-NMR spectra confirmed the structures of the products. The formation of the 
pyrazoline analogues 68 and 69 was first recognized by the disappearance of the a,~­
unsaturated ketone linker protons, which appear as doublets around 7.2-8.1 ppm with 
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protons, with the chiral centre proton (H-1 5) appearing as a ddd (coupling to NH and 
2x H-16) at 5.4 ppm and the other two protons at the adjacent carbon observed at 3.9 
and 3.13 ppm. Further evidence from the 13C_NMR spectra was observed from the 
disappearance of the carbonyl carbon (C=O) chemical shift in the region 187-192 
ppm. The molecular ions observed in the mass spectra confirm the molecular weights 
of the pyrazoline derivatives formed. Elemental analyses confirmed the molecular 
formulae and the purity of the compounds. 
OCH3 
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The structures of N '-substituted pyrazoles 75-84 were confirmed by the slight 
downfield shift of the chiral centre proton (H-15) and the protons on the adjacent 
carbon in the IH-NMR spectra. This shift is due to the electron-withdrawing ability of 
the sulfonyl urea group attached to one of the nitrogen atoms of the pyrazoline ring. 
The chiral centre proton shifted slightly from 5.4 ppm to 5.82 ppm, while on the other 
hand the protons on the adjacent carbon shifted slightly from 3.9 and 3.13 ppm to 4.16 
and 3.34 ppm respectively. In the sulfonyl ureas H-15 appears as a dd (coupling to 2x 
H-l6) confirming NH substitution. 
H-20, H-22 
J21. H- 4 
H-4\ t H- Jl 
H-J9, H-23 I 
NH 
H-8 H-5 
1---t---H-J3, H- 7 
H-J6 
H-J5 
I I I i I I I I t j I 1 I j I I I I I I I I I ) I I I I I I I I I I I I I IT I I I j 
XII 7 :. 7\1 (,0 5 0 














Alternative synthesis of a potent Bisquinoline chalcone and its analogue 
Bisquinoline chalcone 85 was previously designed as part of a bitherapeutic strategy 
in which a haem-binding (bis)quinoline moiety is attached to an electrophilic linker in 
such a way that the two quinoline moieties are placed on either side of the 
electrophilic linker. The electrophilic a,p-unsaturated linker was expected to inhibit 
falcipain-2 by alkylation of the protease active site thiol. The low nanomolar (ICso = 7 
nM) potency of chalcone 85 against a chloroquine resistant W2 strain is noteworthy 
(M. Gamildien; E. Sickle; K. Chibale: unpublished data). This compound also inhibits 
the Plasmodiumfalciparom cysteine protease falcipain-2 (lCso = 3.4 IlM). We decided 
to explore an alternative synthesis with a view to improving the yield of compound 
85, which would in turn allow preparation of sufficient quantities for in vivo (animal) 
experiments. The previous synthesis utilized Mitsunobu chemistryI07-111 (Ph3P, 
DEAD, Et3N) as the key step (M. Gamildien; E. Sickle; K. Chibale: unpublished 
data). Unfortunately this approach resulted in poor yields for the Mitsunobu key step. 
As an alternative protocol, we decided to use standard SN2 chemistry to construct the 
required ether bonds. The retrosynthetic analyses of both the Mitsunobu as well as 
SN2 are summarized in scheme 21. Both analyses require key intermediate 89 which 
was readily prepared from the commercially available 4,7-dichloroquinoline and 
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95 
HN~O~ .aO~'NH I J I . ~A. h /' '" o./~/ .. ~ .. I . I· • 
CI~~N) R 0 85; R = OMe l.:::::-N . ~CI 
86; R = H 
87; R= OMe 
II 
C-O 









SN2 . : ether 
'v/ 
Scheme 21: Retrosynthetic analysis of compound 85 





The intermediate alcohol 89 was prepared from the neat nucleophilic substitution 
reaction of 4, 7-dichloroquinoline 95 with ethanolamine 96 under reflux for 5 hours. lI2 
Triethylamine (0.3 equiv.) and anhydrous potassium carbonate (0.3 equiv) were used 
to facilitate the reaction. The product 89 was obtained in 99 % yield as an off-white 
powder. The alcohol 89 was then converted into mesylate 92 via another nucleophilic 
substitution reaction with methanesulfonyl chloride 94 in pyridine at 0 0c.1l3,114 The 
mesylate 92 was obtained in 71 % yield as a white powder after recrystallization. The 
resulting mesylate 92 was then reacted with 4' -hydroxybenzaldehyde 90, 4'-
hydroxy acetophenone 91 and 4' -hydroxy-2-methoxybenzaldehyde 93 in DMF under 
reflux, to yield the compounds 86-88 in 53 %, 84 % and 58 % yields, respectively as 
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hydroxide as a catalyst in methanol (Claisen-Schmidt condensation). A minimum 
amount ofTHF (co-solvent) was used because the starting materials were insoluble in 
methanol. The chalcone 85 was obtained as a bright yellow powder after column 
chromatography, in 38 % yield (scheme 22). The new synthetic procedure employed 
was not better than the old one, because it did not improve the yield of the final 
chalcone analogue 85. However, the number of purification steps was reduced, 
because there was no need to purify the intermediate analogues 86-88 by column 







Cl~~N/ R 0 
R = Rl = H, 86 
R =H, R 1 =CH3• 88 
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I ' HOiC;:l1( l, / Rl 
R 0 
R = Rl = H, 90 
R H, R 1 := CHa, 91 
R OCH3 , Rl H,93 
Scheme 22: Reagents and conditions: (i) Et3N (0.3 equiv.), K2C03 (0.3 equiv.), reflux, 
5hrs, 99%; (ii) Pyridine, 0 cC, 5 hrs, 71%; (iii) K2C03 (1.1 equiv.), DMF, reflux, 58%, 
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CHAPTER 4 
BIOLOGICAL RESULTS AND DISCUSSION 
4.1 Data against Cysteine proteases (Falcipain-2 , Cruzain, Rhodesain), and 
chloroquine resistant W2 strain of P.falciparum 
Table 6: IC50 values of selected thiosemicarbazones against Falcipain and 
chloroquine resistant (W2) strain of P. Jalciparum. 
x 
NJl H U~ ~ 'N Y o:~ N Y I /' ~ /~ R3 
! H Rl~ "" ""I W 'l( /'/' ~w 1 n 
/? N~R2 X 'NAy 
42,49,59 H x 61 43-48, 51, 52 
3840 
Falcipain W2 
r-4_3_-+I_S_-+,_S_C_H_3 __ +I_H I H :' __ 114.17~' >JO 
44 NH, 16- I CI 116.70 >10 
I 
. OMe I' , I 














Chapter 4 Biological Results and Discussion 
4.1.1 Thiosemicarbazones: Falcipain-2 and P.falciparum SAR (Table 6) 
Discussion of results 
Most compounds failed to inhibit the target enzyme falcipain-2 at the set 
concentration limit of 20 11M. The exceptions (43, 44, 48 and 59) were weak 
inhibitors. Of these, only 59 showed modest efficacy against the chloroquine resistant 
W2 strain. Although comparison to chloroquine, a 4-aminoquinoline structurally 
different from the compounds under study is not appropriate, it is noteworthy that the 
ICso of chloroquine in the same strain is around 0.3 11M. The other compounds (49 
and 52) with some weak or modest efficacy against the W2 strain failed to inhibit the 
target enzyme at 20 11M. There was generally no correlation between the ability of a 
compound to inhibit falcipain-2 and antiplasmodial activity against W2 in vitro. This 
suggests that falcipain-2 is not the target of these compounds. Compounds (49. 52 and 
59) with modest antimalarial activity against W2 maybe acting via a protease-
independent mechanism. It is also possible that compounds 49, 52 and 59 may be 
acting through inhibition of another cysteine protease not contained in our screen. 
This is because there are many cysteine proteases in Plasmodium Jalciparum some of 
which have not been fully identified and characterized. Given that these compounds 
have the ability to chelate a transition metal and it is likely that this mechanism of 
action is responsible for the observed modest antimalarial activity. 
4.1.2 Thiosemicarbazones: Cruzain and Rhodesain SAR (Table 7) 
Discussion of Results 
The data presented in 'rable 7 partly indicates activity of the enzyme (cruzain or 
rhodesain) in the presence of 10 11M of the compounds. If a compound is an effective 
inhibitor, the enzyme activity should be reduced in the presence of such an inhibitor at 
a given concentration. Relatively speaking, low % enzyme activity values imply 
inhibition of the enzyme. Consequently, ICso values were generally only determined 
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Table 7: % Activity of Cruzain and Rhodesain in the presence of 10 JlM of selected 
thiosemicarbazones 
H 
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Compared to falcipain-2, the SAR data against cruzain and rhodesain is striking in 
that a number of compounds were potent in the low micromolar range. In this regard, 
compounds 38, 48 and 59 are noteworthy. Against cruzain, compounds 38 and 48 
were the most effective. These compounds are structurally different and direct 
comparison is not quite appropriate. In comparing activity against cruzain, it is 
necessary to look at compounds from the same structural series. Compounds 38, 39 
and 40 are 4-substituted quinoJines. From this series, the most potent compound (38) 
is a thiosemicarbazone. The corresponding thioester 39 was essentially inactive. The 
poor activity with 40, a semicarbazone underscores the importance of the 
thiosemicarbazone moiety compared to the corresponding semicarbazone moiety in 
the inhibition of cruzain. This result is consistent with earlier findings by Du and 
coworkers.49 Although 3-substituted quinolines are missing from these preliminary 
SAR studies against cruzain, a comparison between compound 38 (4-substituted 
quinoline) and compound 42 (2-substituted quinoline) suggests that the 4-position in 
the quinoline nucleus is a favorable position against cruzain. 
Against rhodesain, many more compounds were effective as compared to cruzain 
although the basis SAR was similar. Compounds 38, 42, 44, 48 and 59 were effective 
against rhodesain in the low to mid micromolar range. As with cruzain, the most 
effective compound (38) is a 4-substituted quinoline. This once again indicates that a 
thiosemicarbazone moiety at this position may be important for binding to cysteine 
proteases within a series of substituted quinolines. Consistent with observations by Du 
and coworkers49, Nl NHrsubstitution was found to lower potency against cruzain for 
thiosemicarbazones. The same trend was observed for rhodesain in this study. This 
fact is highlighted by the results obtained from compounds 42 and 49. Previous 
studies on unrelated aromatic thiosemicarbazones have highlighted the importance of 
the C=S double bond of the thiosemicarbazones in the inhibition of cruzain.49 In our 
study, this was indeed also confirmed against both cruzain and rhodesain when 
comparing thiosemicarbazones and corresponding semicarbazones (38 vs 40; 44 vs 
45; 46 vs 47). The effect of the substituents at position 5 (R3 at the imine carbon 
(C=N)) was most evident when comparing compounds 42 and 59. The compound (59) 
with a methyl substituent was more potent than the compound (42) without this 
substituent. Once again this result is consistent with data reported for the unrelated 
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Within the limited series of compounds, preliminary SAR data against the protease 
targets gives some insight into the significant differences in the active site topology 
between all three (falcipain-2, cruzain and rhodesain) related target proteases. On one 
hand more inhibitors of rhodesain were identified while on the other hand there were 
no (as) effective inhibitors of falcipain-2. This may suggest that rhodesain is a 
promiscuous parasite protease which accommodates a broad range of inhibitors. 
Nevertheless it is clear based on the data against cruzain and rhodesain that quinoline-
based thiosemicarbazones can bind to a cysteine protease target. These findings are in 
agreement with those by Greenbaum et al.57 The mode of inhibition maybe by 
reversible alkylation of the protease active site cysteine thio) requiring nucleophilic 
addition to either the imine (C=N) carbon or the thiocarbonyl (C=S) group of the 
thiosemicarbazone moiety. Alternatively the mode of inhibition may be metal-
interactive inhibition in which the protease active site thiol (in the thiolate form) 
coordinates to the metal complex formed between the thiosemicarbazone moiety and 
endogenous metals such as Fe 2+/Fe3+, Cu2r, Zn2~ and Cd2 '. 
In this preliminary study of quinoline thiosemicarbazones, we endeavored to expand 
SAR ofthiosemicarbazones against parasite cysteine proteases and hence building on 
work conducted in our laboratories.55,57 Although the focus of the work was on 
Plasmodium Jalciparum and falcipain-2 from this parasite, we also screened 
exploratory compounds against two other parasitic cysteine proteases, cruzain and 
rhodesain. In so doing we were not only able to analyze SAR across three related 
parasitic cysteine proteases, but we also identified a novel scaffold (compound 59) 
that exemplifies a more broadly acting scaffold capable of inhibiting cysteine 
proteases from multiple protozoan parasites. Incidentally this scaffold is capable of 
tridentate metal chelation via the sulfur, hydrazinic and quinoline nitrogen atoms 
(figure 17). This compound may be acting as a tridentate metal-interactive cysteine 
protease inhibitor. As far as inhibiting the groMh of Plasmodium Jalciparum is 
concerned, compound 59 may be acting as an iron chelator in P. Jalciparum. 
Tridentate chelating thiosemicarbazones have been shown to inhibit ribonucleotide 
reductase, an enzyme essential for DNA synthesis.m ,ll6 Lastly, evidence exists that 
suggests that copper complexes of thiosemicarbazones produce significant oxidative 
stress by binding endogenous reducing agents such as glutathione. Ultimately, we 
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inhibitors of both cruzain and rhodesain against the parasite sources, T cruzi and T 
brucei, but also the ineffective compounds. This is because the combined data may 
reveal hidden target complexity as has been recently reported.57 
Figure 17: Tridentate metal chelation of compound 59; M = metal; Ln ligands 
4.1.3 Compliance to Lipinski's Rule 
As earlier mentioned factors that have been considered as a primary guide to 
correlating physical properties with successful drug development by prevIOus 
researchers are; lipophilicity, molecular weight, and the number of hydrogen bond 
donors and acceptors. 102-104 Lipinski's "rule of 5" states that for an oral drug candidate 
to have good absorption and permeability the following criteria should be met: 
i) Molecular weight < 500 
ii) CLogP < 5 
iii) Number of H-bond acceptors (expressed as the sum of nitrogen atoms and 
oxygen atoms) ::; 10. 
iv) Number ofH-bond donors (expressed as the sum ofN-H and O-H)::; 5. 
Most of these thiosemicarbazones meet these criteria, and any drug-like compound 
which meets any three of the four criteria set by Lipinski has potential to be developed 
as an oral drug. However, only the most potent compounds in the series of 
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4.2 Data against the chloroquine sensitive strain (010) of Plasmodium!alciparum 
Pyrazoline Analogues of Chalcones 




66; R1 = OCH3 









j 80.20 i CH3 . 68.18 









182 CH3 I: i CI 88.29 i 109.67 58.4~---l ! 83 IOCH3 IF ' 85.13 167026 74.24 ~ .. ~~. 
/H 84 ! Cf.h IF I 86.61 81.18 , 71.02 












4.2.1 Pyrazoline Analogues of Chalcones 
Discussion of Results 
Biological Results and Discussion 
Since one of the initial aims of the project was to conduct a preliminary 
comparative study of chalcones and corresponding unsubstituted and N-
substituted sulfonyl urea derivatives, the IC50 values for each compound were not 
determined. Instead the effect of each compound on malarial parasite viability 
(survival) at three different concentrations was studied. The results are presented 
in Table 8 above. As can be seen from the table, all compounds were generally not 
effective at the tested concentrations. At any given concentration, the % parasite 
viability should be substantially low for an effective antiplasmodial agent. Besides 
the general lack of potency of all derivatives, interpretation of the data was made 
much more difficult by the inconsistent data obtained from the biological testing. 
The expected trend was to be such that the % parasite viability should increase 
with decrease in the concentration of each compound. This expected trend was 
observed in only a few cases for compounds 67, 69 and 81. The inconsistent 
biological data casts doubt on the validity of such data. These experiments need to 
be repeated and more consistent results obtained. 
Although the manner in which the compounds may have been handled at the 
biological testing site is not known, instability and/or precipitation of the 
compounds under the test conditions cannot be ruled out and need thorough 
investigation in future. However, suffices to conclude that all compounds were too 
inactive to permit meaningful comparisons at a given concentration. 
4.3 CONCLUSION 
Most of the thiosemicarbazones were not potent against falcipain-2 and the W2 
strain of P. jalciparnm, but a few compounds (43, 44, 48 and 59) were weak 
inhibitors with compound 59 being the most effective against the chloroquine 
resistant W2 strain. However, various potential inhibitors of cruzain and rhodesain 
have been identified in this study. Compounds 38 and 48 were the most effective 
against cruzain while there were more compounds (38, 42, 44, 48 and 59) that 
were effective against rhodesain. Comparison within each series of compounds 
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and rhodesain. Though comparison between the three series is inappropriate, the 
data shows that the 4-position in the quinoline nucleus is a favorable position 
against both cruzain and rhodesain. Therefore, future work should include 
evaluation of this 4-substituted quinoline compound against the causative agents, 
T. cruzi and T. brucei. Furthermore SAR studies on the 4-substituted quinoline 
compound should be carried out. These SAR studies should include the variation 
of the group attached to C-5 (C=N) of the thiosemicarbazone moiety. Substitution 
of alkyl groups on the C-5 carbon could enhance the activity of this compound 
against all three cysteine proteases (cruzain, falcipain-2 and rhodesain), the result 
of which is observed when comparing compounds 42 and 59. As alluded to 
earlier, compounds that combine pharmalogical activities may be advantageous or 
disadvantageous. In the case of thiosemicarbazones, the combination of 
pharmalogical activities against the cysteine proteases (cruzain, falcipain-2 and 
rhodesain) is advantageous. 
The pyrazoline analogues of chalcones were generally not effective at the tested 
















Proton nuclear magnetic resonance eH NMR) spectra were recorded at ambient 
temperature using the following instruments: Varian Mercury (300MHz) or Varian 
Unity Spectrometer (400MHz) and TMS was used as an internal smndard. The 
chemical shifts (0) are given in ppm relative to TMS (0 0.00). 
Carbon-13 nuclear magnetic resonance (i3C NMR) spectra were recorded at 75MHz 
or 100MHz with the same internal standard. Diverse solvents were used in the 
determination of spectra for different compounds. The chemical shifts (0) are given in 
ppm relative to TMS (0 = 0.00). 
The following abbreviations were used in the IH NMR spectra: s, singlet; d, doublet; 
dd, double doublet; ddd, double double doublet; t, triplet; q, quartet; m, multiplet; and 
J, coupling constant. 
Mass spectra were recorded by means of a VG micromass 16 F spectrometer at 70eV 
with accelerating voltage 4kV. Accurate masses were determined using a VG-70E 
spectrometer (at Cape Technikon, South Africa) and VG (Micromass) 70-SE 
magnetic sector mass spectrometer (at Kent, UK). Other mass spectra were recorded 
by means of micromass 70-70E double focusing magnetic sector mass spectrometer 
fitted with an Ion Tech B II N saddle field F AB gun (Ion Tech Ltd, Teddington, UK) 
and a VGll-250J Data system and micromass Autospec-TOF double focusing 
magnetic sector mass spectrometer (at University ofPotchefstroom, South Africa). 
Infrared spectra were measured either in solution form using chloroform or as solids 
(KBr pellets) or Nujol mulls on a satellite FT-IR spectrophotometer. 












Chapter 5 Experimental 
Melting points were determined by using a Reicher-Jung Thermovar (temperature 
range 0-350 0c) on cover slips and are uncorrected. 
Column chromatography and preparative layer chromatography (p.l.c), carried out on 
silica gel (Merck Kieselgel 60) were used in purification of samples. 
Reactions were monitored by thin-layer chromatography (tic) using coated silica gel 
plates, detection by an ultra-violet lamp. 
Commonly used solvents were purified and dried accordingly as described in the 
literature. 
Anhydrous sodium sulphate and anhydrous magnesium sulphate were used in the 
drying of organic solvents after extraction. 
Concentration of organic phase (removal of solvents) was achieved by using a Buchi 
Rotary Evaporator under reduced pressure. 
Below is the general numbering system that is used for the quinoline ring system. 
s 4 
6~. 4a/~ 
r, "'V '.:::::13 :! I 
7~~ ~2 














Cruzain and Rhodesain 
Recombinant cruzain (from T. cruzi) and rhodesain (from T. brucei rhodesien'.e) 
were recombinantly expressed as previously described by Du and coworkers.49 
Cruzain (2 nM) and rhodesain (3 nM) were incubated with 0.1-20 11M inhibitor in 
100 mM sodium acetate, pH 5.5 containing 5 mM DTT buffer, for 5 minutes at 
room temperature. The buffer containing Z-Phe-Arg-AMC (Bachem, Km = 111M) 
was added to the enzyme-inhibitor reaction to give a 20 11M substrate 
eoncentration. The increase in fluorescence (exeitation at 355 nM and emission at 
460 nM) was followed with an automated microtitre plate spectrofiuorimeter 
(Molecular Devices, spectraMAX Gemini). Inhibitor stock solutions were 
prepared at 20 mM in DMSO, and serial dilutions were made in DMSO (0.7 % 
DMSO in assay). Controls were performed using enzyme alone, and enzyme with 
DMSO. ICso values were determined graphically using inhibitor concentrations in 
the linear portion of the plot of inhibition versus log [IJ (seven concentrations 
were tested, and at least two were in the linear range). 
Percentage activity of the cysteine proteases (cruzain and rhodesain) were 
determined at 10 11M concentrations of the inhibitor. ICso values were determined 
for only the compounds that had less than 50 % activity of the cysteine proteases 
(cruzain and rhodesain). 
IC50 values against recombinant falcipain-2 was determined as previously 
described by Rosenthal and coworkers.117 The enzyme (falcipain-2) was incubated 
for 30 minutes at room temperature in 100 mM sodium acetate, pH 5.5 containing 
10 mM DTT buffer with different concentrations of tested inhibitors. Inhibitor 
solutions were prepared from stock in DMSO (maximum concentration ofDMSO 
in the assay was 1 %). After 30 minutes of incubation, the substrate Z-Leu-Arg-
AMC (benzoxycarbonyl-Leu-Arg-7amino-4-methyl-eoumarin) in the same buffer 
was added to a final concentration of 25 11M. Fluorescence was monitored for 15 
minutes at room temperature in a Fluroskan Ascent spectrofiuorometer 
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over compound concentration using data analysis program Prism (GraphPad 
software). 
P. Jalciparum culture assay 
W2 strain of P. Jalciparum parasites (1 % parasitemia, 2 % hematocrit) were 
cultured in 0.5 ml of medium in 48-well culture dishes.1I8 Selected inhibitors from 
10 mM stocks in DMSO were added to cultured parasites to a final concentration 
of 20 ~M. From 48-well plates, 125 ~L of culture was transferred to two 96-well 
plates (duplicates). Serial dilutions (l :5) of inhibitors were made to final 
concentrations of I 0 ~M, 2 ~M, 400 nM, 80 nM, 16 nM and 3.2 nM. Cultures 
were maintained at 37°C for two days. The parasites were washed and fixed with 
I % formaldehyde in PBS. After two days, parasitemia was measured by flow 
cytometry using the DNA stain YOYO-I as a marker for cell survival. 
5.2.2 Chalcones and Pyrazoline derivatives 
Data against the Chloroquine-sensitive strain of P.falciparum (DID) 
All samples were tested in duplicate on a single occasion against the chloroquine-
sensitive strain of P. Jalciparum (D 10). Continuous in vitro cultures of asexual 
erythrocyte stages of P. Jalciparum were maintained using a modified method of 
Trager and Jensen. 1I8 Quantitative assessment of antiplasmodial activity in vitro 
was determined via the parasite lactate dehydrogenase assay using a modified 
method described by Makler and coworkers. 119 The average percentage parasite 
viability is determined at three different concentrations. 
Samples were stored at -20°C until use. The pre-weighed samples were first 
dissolved in I 000 ~L of 100 % DMSO to give a 2 mg/mL concentration each. The 
samples were then diluted with water to reach the desired concentration of 20 
~g/mL. All samples were further diluted to 2 J.1g/mL in complete medium on the 
day of the experiment. The highest concentration of DMSO to which the parasites 
were exposed to had no measurable effect on the parasite viability. Chloroquine 




















1 2-(7-Chloro-quinolin-4-ylamino )-ethanol (89). A solution of 
4,7-dichloroquinoline (7.50 g; 37.87 mmol), ethanolamine (46 ml; 757 mmol), 
triethylamine (1.6 ml; 11.36 mmol) and anhydrous potassium carbonate (J .57 g; 11.36 
mmol) was stirred under reflux at 120-140 °c for 5 hrs. The reaction mixture was then 
cooled to room temperature during which a precipitate formed. It was then filtered, 
washed with water and recrystallised from methanol to obtain the product 89 (8.34 g; 
99 %) as an off .. white powder. mp: 216 .. 218 °c (from methanol), Rf (methanol: 
dichloromethane, 1 :9) 0.17; Vmax (KBr)/ cm-
I 3618 (O-H), 3305 (N .. H), 3029 (C .. H; 
aromatic), 1578 (C=C). bH (400 MHz, DMSO .. d6) 8.36 (d, IH, J 5.4 Hz, H .. 2), 8.23 (d, 
t H, J 8.8 Hz, H .. 5), 7.76 (d, 1 H, J 2.0 Hz, H .. 8), 7.41 (dd, I H, J 2.0 and 8.8 Hz, H-6), 
7.22 (s, I H, NH), 6.48 (d, 1 H, J 5.4 Hz, H .. 3), 3.65 (t, 2H, J 5.8 Hz,2x H .. JO), 3.34 (1, 
2H, J 5.8 Hz, 2x H .. 9). be (100 MHz, DMSO-d6) 152.59 (C .. 2), 150.95 (C-4), 149.82 
(C .. 8a), 134.03 (C .. 7), 128.19 (C .. 8), 124.77 (C .. 6), 124.67 (C .. 5), 118.18 (C .. 4a), 99.40 
(C-3), 59.48 (C .. JO), 45.85 (C .. 9). Anal Found: C, 59.67; H, 4.63; N, 12.58 %. Calc. 
for CIl H"CIN20: C, 59.33; H, 4.98; N, 12.58 %. Calc. for C ll H"ClN20; mlz 222.7. 
Found MS (FAB) mlz 223.0 (M+lf. 
(7 .. Chi 0 ro-q ui n olin -4-yl )-(3-m ethan esulfony 1-
propyl)amine (92). A solution of compound 89 (2.0 g; 9.0 mmol) in 6ml of pyridine 
was stirred at 0 °C for 30 min. To the above solution, was added a solution of 
methanesulfonyl chloride (1.74 mJ; 22.52 mmol) in 5.40 ml of pyridine and the 
reaction mixture was stirred at 0 °C for 5 hrs. It was then diluted with 17% ammonium 
hydroxide, extracted in dichloromethane, dried over anhydrous MgS04• concentrated 
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g; 71 %] as a white powder. mp: 139-142 °c (from ethyl acetate-hexane), Rf 
(methanol: dichloromethane, 1 :9) 0.27; Vrnax (KBr)/ em-I 3218 (N-H), 1579 (C=C). OH 
(300 MHz, CDCh) 8.57 (d, IH, J5.4 Hz, H-2), 7.98 (d, lH, J2.4 Hz, H-8), 7.73 (d, 
1 H, J 8.8 Hz, H-5), 7.41 (dd, 1 H, J 2.4 and 8.8 Hz, H-6), 6.42 (d, I H, J 5.4 Hz, H-3), 
4.59 (t, 2H, J 5.7 Hz, 2x H-lO), 3.70 (t, 2H, J 5.7 Hz, 2x H-9), 3.08 (s, 3H, S02CH3). 
oe (75 MHz, CDCh) ISI.94 (C-2), 149.09 (C-8a, C-4), 135.73 (C-7), 128.92 (C-8), 
125.92 (C-6), 121.10 (C-5), 118.54 (C-4a), 99.04 (C-3), 66.80 (C-lO), 42.49 (C-9), 
37.86 (CH3) . Anal Found: C, 48.07; H, 4.39; N, 9.32; S, lO.60 %. Calc. for 
C 12H13ClN20S: C, 47.92; H, 4.36; N, 9.31; S, 10.66 %. Calc. for C I2H13CIN20S; m/z 
300.8. Found MS (FAB) m/z 301.0 (M+l),. 
General procedure for the preparation of compounds 86-88 
A solution of compound 92 (O.SO g; 1.67 mmol), respective 4-hydroxybenzaldehyde 
or 4-hydroxyacetophenone (1.67 mmol) and anhydrous potassium carbonate (0.25 g; 
1.84 mmol) in 5 ml of DMF was stirred under reflux for 3hrs with TLC monitoring. 
The reaction mixture was cooled to room temperature, then diluted with distilled 
water and extracted in ethyl acetate, washed with saturated sodium chloride solution, 
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8 1 4-[2-(7 -Chloro-quinolin-4ylamino )-ethoxy 1-
benzaldehyde (86). Yield: 0.32 g; 58 %, obtained as an off-white powder mp: 17S-
176°C (from methanol), Rf(methanol: dichloromethane, 1: \9) 0.20; Vrnax (KBr)/ cm- I 
3342 (N-H), 2920 (C-H, aliphatic), 1705 (C=O), 1573 (C=C). BH(400 MHz, DMSO-
d6) 9.85 (s,IH, CHO), 8.41 (d, IH, JS.2 Hz, H-2), 8.26 (d,lH, J9.2 Hz, H-5), 7.84 (d, 
2H, J9.0 Hz, Hb,Hb'), 7.78 (d, lH, J2.0 Hz, H-8), 7.45 (dd,lH, J2.0 and 9.2 HZ, H-
6), 7.14 (d, 2H, J 9.0 Hz, Ha,Ha), 6.60 (d, 1 H, J 5.2 Hz, H-3), 4.36 (t, 2H, J 5.6 Hz, 
2x H-lO), 3.72 (1, 2H, J 5.6 Hz, 2x H-9). Be (100 MHz, DMSO-d6), 193.98 
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(C-b,b '),130.47 (C-d), 128.22 (C-8), 124.90 (C-6), 124.74 (C-5), 118.14 (C-4a), 115. 
69 (C-a.aj, 99.66 (C-3), 66.85 (C-10), 42.50 (C-9). Anal Found: C, 65.87; H, 4.67; 
N, 8.05 %. Calc. for C18H1SCIN20 2 : C, 66.16; H, 4.63; N, 8.57 %. Calc. for 
ClsHI5CIN202; mlz 326.8. Found MS (FAB) mlz 327.1 (M+lf. 
9 a' 
HN/~/000'~ b' 
5 14 10 I d 
;0:'. ~~3 a h . " .. J b '. CI ,. ;sa ~~2 0 
1-{4-[2-(7 -Chloro-quinolin-4ylamino )-ethoxy)-
phenyl}-ethanone (88). Yield: 0.30 g; 53 %, obtained as off-white powder mp: 173-
175°C (from methanol), Rr (ethyl acetate: hexane, 1:4) 0.18; Vmax (KBr)/ em-I 3382 
(N-H), 3200 (C-H, aromatic), 2935 (C-H, aliphatic), 1691 (C=O), 1581 (C=C). 8H(400 
MHz, CDCh), 8.58 (d, I H, J 5.2 Hz, H-2), 7.99 (d, IH,.f 2.0 Hz, H-8), 7.95 (d, 2H,.f 
9.2 Hz, lib, lib ,), 7.70 (d, IH, J 9.2 Hz, H-5), 7.39 (dd, 1 H, J 2.0 and 9.2 Hz, 11-6), 
6.98 (d, 2H, J 9.2 Hz, lIa,Ha'), 6.51 (d, IH,.f 5.2 Hz, 11-3), 4.36 (t, 2H, J 5.6 Hz, 
2xH-1O), 3.78 (t, 2H, J 5.6 Hz, 2xH-9), 2.56 (s, 3H, ArC=OCII3). be (100 MHz, 
CDCb) 179.56 (C=O), 162.06 (C-c), 151.93 (C-2), 149.41 (C-4), 149.30 (C-8a), 
135.17 (C-7), 130.68 (C-b,b '), 129.71 (C-d), 129.67 (C-8), 128.92 (C-6), 125.71 (C-
5), 120.84 (C-4a), 114.23 (C-a,a'), 99.31 (C-3), 66.00 (C-1O), 42.43 (C-9), 26.30 
(CH3) Calc. for C]9H 17CIN202 mlz 340.8. Found MS (FAB) mlz 341. I (M+I f. 
4-[2-(7-Chloro-quinolin-4ylamino)-ethoxy]-2-
methoxy-benzaldehyde (87). Yield: 0.50 g; 84 %, obtained as an off-white powder. 
mp: 132-134 °c (from methanol), Rf (methanol: dichloromethane, 1: 19) 0.31; Vmax 
(KBr)/ em'] 3394 (N-H), 3205 (C-H, aromatic), 2945 (C-H, aliphatic), 2884 (C-H, 
CHO), 1709 (C=O), 1578 (C=C). bH (300 MHz, CDCh) t 0.30 (s, I H, CliO), 8.59 (d, 
tH, .f 5.4 Hz, 11-2),7.99 (d, IH, J 2.1 Hz, H-8), 7.83 (d, IH, J 9.0 Hz, Hb), 7.70 
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Ha), 6.50 (m, 2H, He and H-3), 4.37 (t, 2H, J 5.2 Hz, 2xH-10), 3.89 (s, 3H, OCH3), 
3.79 (t, 2H, J 5.2 Hz, 2xH-9). Oc (75 MHz, CDCb) 191.23 (CHO), 164.72 (Cj), 
163.61 (C-d), 152.00 (C-2), 151.04 (C-4), 149.40 (C-8a), 135.14 (C-7), 130.86 (C-b), 
128.96 (C-8), 125.70 (C-6), 120.94 (C-5), 119.68 (C-4a), 117.32 (C-c), 106.06 (C-a), 
99.32 (C-3) , 98.58 (C-e), 66.14 (C-10), 55.68(OCH3), 42.44(C-9). Anal Found: C, 
63.85; H. 5.10; N, 7.43 %. Calc. for CI9H17CIN203: C, 63.96; H, 4.80; N, 7.85 %. 
Calc forC19H17CIN203 mlz 356.8(M+lf. Found MS (FAB) mlz 357.1 (M+lf. 
9 a h' . 9' 
HN~OVOb g' J O~'NH 
5 4 10 II c mil 10' 4i4a'Ji' 
6~~3 e h ~ • 0., h 31~y~.a ",6' 
~ II lid n 1 9 I I· 7' 
 -;/2 OMe 0 2'~' h 
CI 7 8 8a'~ ~8a' 8' CI 
3-{4-[2-(7 -Chloro-
q uinolin-4-ylamino )-ethoxy J-2-methoxy-phenyl }-1-{4-[2-(7 -chloro-q uinolin-4-yl)-
ethoxy]-phenyl}-propenone (85). A solution of compound 88 (0.1 g; 0.28 mmol) 
and compound 87 (96 mg; 0.28 mmol) in 3ml of methanol (0.5 ml THF, cosolvent) 
was stirred at room temperature for 10 minutes to dissolve the starting materials. 
NaOH (25 mg; 0.56 mmol) was added to the reaction mixture and it was stirred at 
room temperature for 24 hrs. A yellow precipitate was fanned and it was filtered by 
suction, washed with water. Column chromatography (Si(h methanol: 
dichloromethane, 1 :9), yielded the desired product (0.72 g; 38 %) as a yellow powder. 
mp: 143-145 °c (from ethanol), Rr(methanol: dichloromethane, 1 :9) 0.39. Vmax (KBr)/ 
cm-1 3374 (N-H), 3095 (C-H, aromatic), 2976 (C-H, aliphatic), 1669 (C=C, mn), 
1579 (C=C, aromatic). oH(400 MHz, DMSO-d6) 8.43 (d, 2H, J 5.4 Hz, H-2,H-2'), 
8.28 (d, 2H. J2.0 Hz, H-8,H-8'), 8.26 (d, 2H, J9.2 Hz, Hg,Hg), 8.07 (d, 1H, J9.0 
Hz, Hb), 7.93 (d, 1 H, J 16.0 Hz, Hn), 7.87 (d, 2H, J 9.2 Hz, H-5,H-5 '), 7.72 (d, 1 H, J 
16.0 Hz, Hm), 7.45 (dd, 2H, J 2.0 and 9.2 Hz, H-6,H-6), 7.08 (d, 2H, J 9.2 Hz, 
Hh,Hh), 6.64 (d, 1 H, J9.0 Hz, Ha), 6.60 (s, I H, He), 6.51 (d, 2H, J 5.4 Hz, H-3,H-3 '). 
4.35 (1, 4H, J 5.2 Hz, 2xH-IO,2xH-10'), 3.85 (s, 3H, OCH3), 3.71 (t, 4H, J 5.2 Hz, 
2xH-9,2xH-9 '). od75 MHz, DMSO-d6) 187.33 (C=O), 162. 09 (Cj), 162.02 (Cd), 
159.75 (Cj), 151.90 (C-2,C-2'), 149.98 (C-4,C-4'), 149.96 (C-8a,C-8a'), 146.43 (C-
4a,C-4a'), 137.78 (Cn), 133.40 (C-7,C-7'), 130.91 (Cg,Cg'), 130.57 (0),127.50 (C-











h,C-h'), 114.38 (C-c), 106.77 (C-a), 98.90 (C-3,C-3'), 98.74 (Ce), 65.90 (C-IO,C-
10'), 55.77 (Oel-h), 41.86 (C-9,C-9'). Calc. for C38H32CbN404, mlz 679.18788 
(M+lf. Found HRMS (FAB) mlz 679.18725 (M+lf. 
General procedure for preparation of compounds 38, 41, 44, 46, 48, 59, 61 
A mixture of the appropriate quinolinecarboxaldehyde (1.0 equiv.) and 
thiosemicarbazide (1.0 equiv) were added to 5 ml of warm ethanol (50°C) and the 
reaction mixture was stirred for 3 hrs at 50°C. It was then left to stand at room 
temperature overnight to enhance precipitation and filtered by suction to afford the 
desired products. 
N' -Quinolin-4-yl-methylene-thioseminarbazone (38). 
Yield: 0.34 g; 77 %, obtained as a yellowish powder. mp: 241-242 °C (from 
methanol), Rr( ethyl acetate: hexane, 1: 1) 0.18, Vmax (KBr)/ cm -I 3433 (N-H, NH2), 
3261 (N-H), 3138 (C-H, aromatic), 1544 (C=C). OH (300 MHz, DMSO-d6) 11.74 (s, 
1 H, NNFI), 8.94 (d, I H, J 4.5 Hz, H-2), 8.89 (s,l H, HC=N), 8.41 (s, 1 H, NFl), 8.33 (s, 
1 H, NFl), 8.31 (dd, I H, J 1.5 and 8.2 Hz, H-8), 8.17 (d, I H, J 4.5 Hz, H-3), 8.08 
(dd,1 H, J 1.5 and 8.2 Hz, H-5), 7.82 (ddd, I H, J 1.5, 7.2 and 8.2 Hz, H-6), 7.73 (ddd, 
IH, J 1.5,7.2 and 8.2 Hz, H-7). Oc (100 MHz, DMSO-d6) 179.56 (C=S), 150.81 
(HC=N), 149.09 (C-2), 138.54 (C-8a), 138.00 (C-4), 130.53 (C-8), 130.23 (C-7), 
128.10 (C-4a), 125.75 (C-5), 123.71 (C-6), 118.67 (C-3). Anal Found: C, 56.81; H, 
4.25; N, 24.32; S, 13.68 %. Calc for C 11 HlON4S: C, 57.37; H, 4.38; N, 24.33; S, 13.92 
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N'-(2-Cbloro-6-metboxy)-quinolin-3-yl-
metbylene-tbiosemicarbazone (44). Yield: 0.29 g; 71 %, obtained as a yellowish 
powder. mp: 253-255 °c (from methanol), Rf(ethyl acetate: hexane; 1:1) 0.17; Vmax 
(KBr)/ cm -I 3418 (N-H, NH2), 3257 (N-H), 3140 (C-I-t aromatic), 1591 (C=N), 1529 
(C=C). bH(300 MHz, DMSO-d6) 11.79 (s, IH, NNH), 9.19 (s, lH, H-·I), 8.49 (s, lH, 
HC=N), 8,41 (s, IH, NH), 8.19 (s, tH, NH), 7.86 (d, IH, J9.0 Hz, H-8), 7.48 (dd, 
IH, J 2.7 and 9.0 Hz, H-7), 7.32 (d, IH, J 2.7 Hz, H-5), 3.92 (s, 3H, OCH3). bc(lOO 
MHz, DMSO-d6) 179.18 (C=S), 158.69 (HC=N), 146.56 (C-6), 143.76 (C-2), 137.57 
(C-8a), 135,43 (C-4), 129.92 (C-8), 128.91 (C-4a), 126.94 (C-3), 124.71 (C-7), 
106.60 (C-5), 56.29 (OCH3). Anal Found: C, 48.50; H, 3.54; N, J 8.82; S, 10.70 %. 
Calc. for C12H11CIN40S: C, 48.90; H, 3.76; N, 19.01; S, 10.88 %. Calc for 
C12Hll CIN40S ,mlz295.04203 (M+lf. Found HRMS (FAB) mlz 295.04155 (M+I)+. 
N' -(2-Ch loro-8-methyl)-q uinolin-3-yl-methylene-
thiosemicarbazone (48). Yield: 0.23 g; 56 %, obtained as a yellowish powder. mp: 
256-258 °c (from methanol), Rr (ethyl acetate: hexane, 1: I) 0.59; Vmax (KBr)/ cm,1 
3430 (N-H, NI-h), 3233 (N-l-I), 3127 (C-H, aromatic), 1585 (C=N), 1532 (C=C). OH 
(300 MHz, DMSO-d6) 11.75 (s, J H, NNH), 9.26 (s, I H, H-4), 8.52 (s, I H, HC=N), 
8.41 (s, 1 H, NH), 8.22 (s, 1 H, NH), 7.83 (dd, 1 H, J 2,4 and 8.0 Hz, H-5), 7.70 (dd, 
lH, J 2.4 and 8.0 Hz, H-7), 7.58 (t, IH, J 8.0 Hz, H-6), 2.66 (s, 3H, C1l3). 8c(100 
MHz, DMSO-d6) 179.17 (C=S), 148.24 (C-2), 146.77 (HC=N), 137.58(C-8a), 137.04 
(C-4), 136.28 (C-8), 132.14 (C-7), 128.28 (C-6), 127.76 (C-4a), 127.04 (C-5), 126.63 
(C-3), 17.93 (Ar-CH3). Anal Found: C, 51.67; H, 3.93; N, 20.10; S, 11.67 %. Calc for 
C12HllCIN4S: C, 51.70; H, 3.98; N, 20.10; S, 11.50 %. Calc for CI2HllCIN4S, mlz 












thiosemicarbazone (46). Yield: 0.30 g; 74 %, obtained as a yellowish powder. mp: 
270-272 °c (from methanol), Rr(ethyl acetate: hexane, 1:1) 0048; Vmax (KBr)/ cm-I 
3432 (N-H, Nth), 3246 (N-H), 3 135 (C-H, aromatic), 1585 (C=N), 1530 (C=C). 
8H(300 MHz, DMSO-d6) 11.75 (s, 1 H, NNil), 9.19 (s, I H, H-4), 8.50 (s, 1 H, HC=N), 
8041 (s, IH, Nil), 8.20 (s, IH, Nil), 7.85 (d, IH, J8.7 Hz, H-8), 7.68 (dd, IH, J2.0 
and 8.7 Hz, H-7), 7.66 (d, 1 H, J 2.0 Hz, H-5), 2.52 (s, 3H, CH3). 8c(100 MHz, 
DMSO-d6) 179.16 (C=S), 148.26 (C-2), 147.34 (HC=N), 146.30 (C-8a), 138.17 (C-
4),137.61 (C-6), 136.01 (C-7), 134.38 (C-8), 128.17 (C-4a), 127.71 (C-5), 126.78 (C-
3), 21.82 (Ar-CH3) Anal Found: C, 51.30; H, 3.73; N, 20.18; S, 11.56 %. Calc. for 
CI2HIICIN4S: C, 51.70; H, 3.98; N, 20.10; S, 11.50 %. Calc for CI2H11CIN4S. mlz 
279.0471 I (M+lf. Found HRMS (FAB) mlz 279.04748 (M+lf. 
N' -Quinolin-2-yl-methylene-thioseminarbazone (42). 
Yield: 0.34 g, 77 %, obtained as an off-white powder, mp: 232-233 °c (from 
methanol), Rf (ethyl acetate: hexane, 4:1) 0041, Vmax (KBr)/ cm-
l 3391 (N-H, NH2), 
3142 (N-H), 2994 (C-H, aromatic), 1601 (C=N), 1517 (C=C). OH (300 MHz, DMSO-
d6) ) 1.78 (s, ) H, NNil), 8044 (d, 1 H, J 804 Hz, 11-4), 8042 (s, 1 H, Nil), 8.38 (s, 1 H, 
Nil), 8.35 (dd, 1 H, J 1.5 and 804 Hz, H-8), 8.24 (s, I H, HC=N), 8.00 (d, 1 H, J 804 Hz, 
H-3), 7.96 (dd, 1 H, J 1.5 and 804 Hz, H-5), 7.77 (ddd, I H, J 1.5, 6.9 and 804 Hz, 11-6), 
7.61 (ddd, I H, J 1.5, 6.9 and 804 Hz, 11-7). 8c(100 MHz, DMSO-d6). 179.26 (C=S), 
154.59 (HC=N), 148.04 (C-2), 143.27 (C-8a), 136.94 (C-4), 130.58 (C-4a), 129047 
(C-7, C-8), 128.58 (C-5), 127.80 (C-6), 118.80 (C-3) Anal Found: C, 57.17; H, 4.33; 
N, 24.24; S, 13.78 %. Calc. for C II HlON4S: C, 57.37; H, 4.38; N, 24.33; S, 13.92 %. 
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H N'-Quinolin-2-yl-ethylene-thioseminarhazone (59). 
Yield: 0.12 g; 40 %, obtained as a brown powder, mp: 160-162 °c (from methanol), 
Rr(ethyl acetate: hexane, 1:1) 0.51, Vmax (KBr)/ cm-\ 3623 (N-H, NH2)' 3163 (N-H), 
1602 (C=N). 011(400 MHz, CDC b), 8.98 (5, 1 H, NNfI), 8.3 J (d, 1 H, J 8.4 Hz, H-4). 
8.26 (dd, 1 H, J 1.2 and 8.8 Hz, H-8), 8.10 (d, I H, J 8.4 Hz, H-3), 7.82 (dd, I H, J 1.2 
and 8.8 Hz, H-5), 7.74 (ddd, 1 H, J 1.2, 7.2 and 8.8 Hz, H-6), 7.57 (ddd, I H, J 1.2, 7.2 
and 8.8 Hz, H-7), 6.64 (s, 2H, NH2) 2.59 (5, 3H, CH3). oc(lOO MHz,CDCh) 179.53 
(C=S), 153.80 (CH3C=N), 149.30 (C-2), 147.43 (C-8a), 137.62 (C-4), 136.06 (C-4a), 
128.32 (C-8), 128.11 (C-7), 127.40 (C-5), 127.31 (C-6), 120.40 (C-3), 11.98 (CH3). 
Calc for C12HI2N4S; mlz 244.07826 (Mf. Found HRMS (EI) mlz 244.07832 (Mf. 
N'-Quinolin-8-yl-ethylene-thioseminarhazone (61). Yield: 
0.19 g; 44 %, obtained as a yellowish powder, mp: 208-2 J J °C (from methanol), Rr 
(ethyl acetate: hexane, I: I) 0.38, Vmax (KBr)/ cm-' 3 J 69 (N-H), J 603 (C=N). 
oH(300MHz, CDCb) 8.96 (dd, 1 H, J 2.1 and 4.2 Hz, H-2), 8.36 (s, 1 H, NNfI), 8.24 
(dd, IH, J 2.1 and 8.4 Hz, H-4), 7.95 (dd, 1 H, J 1.5 and 8.1 Hz, H-5), 7.64 (t, 1 H, J 
8.1 Hz, H-6), 7.56 (dd, I R J 1.5 and 8.1 Hz, H-7), 7.50 (dd, 1 H,.J 4.2 and 8.4 Hz, H-
3),7.36 (s, lH, Nfl), 6.18 (s, IH, Nfl), 2.46 (s, 3H, CH3). oc(100 MHz, CDCb) 
179.45 (C=S), 152.74 (CH)C=N). 151.74 (C-2), 151.63 (C-8a), 136.81 (C-4), 136.50 
(C-8), 130.36 (C-5), 129.72 (C-7), 129.39 (C-4a), 126.78 (C-6), 122.50 (C-3), 20.79 
(CH). Anal Found: C, 58.13; H, 4.86; N, 22.83; S, 12.92 %. Calc. for C12HI2N4S: C, 
58.99; H, 4.95; N, 22.93; S, 13.12 %. Calc for C 12H I2N4S; mlz 244.07826 (Mf. 
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General procedure for the preparation of compounds 39, 41 and 43 
A solution of the appropriate quinoline-carboxaldehyde (4.01 g; 25.45 mmol) and 
methylhydrazinecarbodithioate (3.11 g; 25.45 mmo!.) in isopropanol (20 ml) was 
stirred at room temperature for 3 hrs, whereby a yellowish-orange precipitate started 
forming. This was filtered by suction, washed with cold isopropanol to afford the 
desired products. 
N' -Quinolin-4-yl-methylene-thiosem inarbazone methyl 
ester (39). Yield: 5.82 g; 87 %, obtained as a yellowish-orange powder. mp: 183-185 
°C (from methanol), Rf (ethyl acetate: hexane, I: 1) 0.50; Vmax (KBr)/ cm·
l 3088 (C-H, 
aromatic), 1537 (C=C). oll(300 MHz, CDCh) 10.40 (s, 1 H, NNH), 9.00 (d, 1 H, J 5.0 
Hz, 11-2), 8.73 (dd, I H, J 1.0 and 8.4 Hz, 11-8), 8.39 (s, tH, IIC=N), 8.19 (dd, 1 H, J 1.0 
and 8.4 Hz, H-5), 7.79 (ddd, 1 H, J 1.0,6.6 and 8.4 Hz, H-6), 7.72 (d, 1 H, J 5.0 Hz, H-
3), 7.68 (ddd, IH, J 1.0, 6.6 and 8.4 Hz, H-7), 2.73 (s, 3H, SCH3). oc(100 MHz, 
CDCh) 200.20 (C=S), 151.06 (HC=N), 149.14 (C-2), 144.86 (C-8a), 137.07 (C-4), 
l30.59 (C-8), 130.43 (C-7), 128.62 (C-4a), 125.l3 (C-5), 125.03 (C-6), 121.90 (C-3), 
17.70 (SCH3). Calc for C I2HllN3S2, m/z 262.04726 (M+I)'". Found HRMS (FAB) m/z 
262.04802 (M+lf. 
N' -Quinolin-3-yl-methylene-thiosemicarbazone 
methyl ester (43). Yield: 6.20 g; 92 %,obtained as a yellow powder. mp: 208-212 °c 
(from methanol), Rr(methanol: dichloromethane, I: I) 0.54; Vmax (KBr)/ cm-1 3077 (N-
H), 1522 (C=C) bll(400 MHz, DMSO-d6) 13.45 (s, IH, NNH), 9.25 (d, lH, J2.0 Hz, 
H-2), 8.59 (d, ] H, J 2.0 Hz, H-4), 8.43 (s, I H, HC=N), 8.07 (dd, I H, J 1.2 and 8.4 Hz, 











7.65 (ddd, IH, J 1.2, 7.0 and 8.4 Hz, H-6), 2.56 (s, 3H, SCH3). <>c(lOO MHz, DMSO-
d6). 189.56 (C=S), 148.67 (C-2), 144.76 (HC=N), 136.56 (C-8a), 131.49 (C-4), 
129.60 (C-7), 129.45 (C-8), 128.23 (C-5), 127.93 (C-6), 127.36 (C-4a), 126.73 (C-3), 
17.52 (SCH3) Anal Found: C, 55.05; 1-1, 4.18; N, 15.62; 1-1, 23.34 %. Calc for 
CI2HliN3S2: C, 55.14; 1-1, 4.24; N, 16.08; S, 24.54 %. Calc. for C 12HlIN3S2, mlz 
262.04726 (M+ If. Found HRMS (F AB) mlz 262.04730 (M+ 1)+ . 
N' -Quinolin-2-yl-methylene-thioseminarbazone 
methyl ester (41). Yield: 5.80 g; 87 %, obtained as a yellow-orange powder, mp: 
197-199 °c (from methanol), Rr (methanol: dichloromethane, 1:19) 0.8; OH (300 
MHz, DMSO-d6 ) 13.59 (s, 11-1, NNH), 8.44 (d, 11-1, J 9.0 I-Iz, H-4), 8.41 (s, lH, 
HC=N), 8.07 (dd, 1 H, J 1.5 and 8.4 I-Iz, H-8), 8.04 (d, 1 H, J 9.0 Hz, H-3), 7.99 (dd, 
1 H, J 1.5 and 8.4 Hz, H-5), 7.81 (ddd, 11-1, J 1.5, 6.6 and 8.4 Hz, H-6), 7.66 (ddd, 11-1, 
J 1.5, 6.6 and 8.4 Hz, H-7), 2.58 (s, 3H, SCH3). 8c(75 MHz, DMSO-d6). 188.56 
(C=S), 154.67 (I-IC=N), 146.70 (C-2), 140.67 (C-8a), 137.S9 (C-4), I3S.60 (C-4a), 
134.48 (C-7, C-8), 129.23 (C-5), 127.33 (C-6), 126.73 (C-3), 17.52 (SCH3). Calc. for 
CI2HIIN3S2, mlz 262.04726 (M+lf. Found I-IRMS (FAB) mlz 262.04730 (M+lf. 
General procedure for the preparation of compounds 49-53 
A solution of thiosemicarbazone thioester (41143) (0.20 g; 0.764 mmol) and 
primary/secondary amine (4.0 equiv) in Sml methanol and co-solvent (lml THF) was 
stirred under reflux for 12 hrs. The solvent was removed in vacuo to afford the 
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N' -Quinolin-3-yl-methylene-l' -piperidine-
thiosemicarbazone (51). Yield: 0.13 g; 57 %, obtained as a yellow powder mp: 174-
176°C (from ethanol), Rr(ethyl acetate: hexane, 3:7) 0.17; Vmax (KBr)/ em-I 3426 (N-
H), 3127 (C-H, aromatic), 2936 (C-H, aliphatic), 1508 (C=C). 8H(400 MHz, CDCb) 
9.26 Cd, 1 H, J 2.0 Hz, H-2), 8.82 (s, 1 H, NNIl), 8.17 (d, I H, J 2.0 Hz, H-4), 8.10 (dd, 
I H, J 1.2 and 8.4 Hz, H-8), 7.84 (dd, 1 H, J 1.2 and 8.4 Hz, H-5), 7.82 (s, 1 H, HC=N), 
7.74 (ddd, 1 H, J 1.2, 7.0 and 8.4 Hz, H-7), 7.58 (ddd, I H, .J 1.2, 7.4 and 8.4 Hz, H-6), 
4.03 (1, 4ft .J 4.4 Hz, 2xHa,2xHa), 1.80 (m, 6H, 2xHb,2xHb ',2xHe). 8d75 MHz, 
CDCh) 186.34 (C=S), 148.14 (C-2), 145.06 (HC=N), 136.77 (C-8a), 130.41 (C-4), 
129.54 (C-7), 129.34 (C-8), 128.12 (C-5), 127.87 (C-6), 127.47 (C-4a), 126.86 (C-3), 
53.27 (C-a,-Ca126.18 (C-e), 24.34 (C-b, C-b'). Anal Found: C, 63.61; H, 5.88; N, 
18.56; S, 10.28 %. Calc. for CI6H1SN4S: C, 64.40; H, 6.08; N, 18.78; S, 10.75 %. 
Calc. for CI6HIsN4S mlz 299.13303 (M+lf. Found HRMS (FAB) mlz 299.13319 
(M+lf. 
N' -Quinolin-3-yl-methylene-l '-(3-
dimethylamino-l-propylamine)-thiosemicarbazone (52). Yield: 0.15 g; 63 %, 
obtained as a yellow powder after column chromatography (Si02, methanol: 
dichloromethane , 1 :9), mp: 195-198 °C (from ethanol), Rr (methanol: 
dichloromethane, 1:9) 0.11; Vmax (KBr)/ cm-
J 3144 (C-H, aromatic), 2942 (C-H, 
aliphatic), 1527 (C=C). BH(400 MHz, CDCb) 9.80 (s, tH, NNIl), 9.35 (s, tH, Nil), 
9.30 (d, tH, J 2.0 Hz, H-2), 8.26 (d, tH,.J 2.0 Hz, H-4), 8.01 (s, IH, HC=N), 8.12 
(dd, IH, J 1.2 and 8.4 Hz, H-8), 7.84 (dd, IH, J 1.2 and 8.4 Hz, H-5), 7.74 (ddd, tH,.J 
1.2, 7.0 and 8.4 Hz, H-7), 7.58 (ddd, I H, J 1.2, 7.0 and 8.4 Hz, H-6), 3.87 (t, 2H, .J 5.2 
Hz, 2x Ha), 2.56 (1, 2H, J 5.2 Hz, 2x He), 2.37 (s, 6H, N(CH3)2), 1.87 (m, 211, 2x Hb). 
Bc(75 MHz, CDCh) 186.98 (C=S), 148.49 (HC=N), 148.19 (C-2.8a), 139.72 (C-4), 
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59.12 (C-e), 45.51 (C-a), 45.45 (N(CH3h), 36.74 (C-b). Calc. for C16H2INsS, mlz 
316.15958 (M+1f. Found HRMS (FAB) mlz 316.15913 (M+lf· 
5 4 H H b H 3' 
6~N/NI(N~~'~c;Y~' 
7~_'N·~h S ,r: N1, 
8 8a 1 5 I . Sa' 
6'hS' 7'1 
CI N' -Quinolin-3-yl-metbylene-l '-(N'-
[7-cbloro-quinoline-4-yllpropane-l,3-diamine)-thiosemica rbazone (53). Yield: 
27.5 mg; 8%, obtained as a yellowish-brown powder after column chromatography 
(Si02, methanol: dichloromethane, 1 :9), mp: 209-212 °c (from ethanol), Rf 
(methanol: dichloromethane, 1 :9) 0.32; Vmax (KBr)/ cm-
1 3278 (N-H), 2936 (C-H, 
aliphatic), 1546 (C=C). oH(400 MHz, DMSO-d6) 11.66 (s, IH, NNIf), 9.52 (d, IH, J 
2.2 Hz, H-2), 8.81 (s, 1H, NIf), 8.53 (d, IH, J2.2 Hz, H-4), 8.40 (d, IH, J 5.6 Hz, H-
2 '), 8.28 (d, 1 H, J 8.8 Hz, H-5 '), 8.23 (s, 1 H, HC=N), 8.03 (dd, 1 H, J 1.2 and 8.4 Hz, 
H-8), 7.97 (d, lH, J 1.8 Hz, H-8'), 7.76 (dd, IH, J 1.2 and 8.4 Hz, H-5), 7.65 (ddd, 
1 H, J 1.2, 7,2 and 8.4 Hz, H-7), 7.60 (ddd, 1 H, J 1.2, 7.2 and 8.4 Hz, H-6), 7.41 (dd, 
1 H, J 1.8 and 8.8 Hz, H-6 '), 6.56 (d, I H, J 5.6 Hz, H-3 '), 3.77 (t, 2H, J 6.8 Hz, 2x 
Ha), 3.02 (1, 2H, J 6.8 Hz, 2x He), 2.04 (m, 2H, 2x Hb). oc(lOO MHz, DMSO-d6) 
186.75 (C=S), 153.43 (C-2'), 149.56 (C-4'), 148.56 (HC=N), 148.13 (C-8a), 147.89 
(C-2,8a), 140.12 (C-4), 139.34 (C-7),135.16 (C-8), 133.43 (C-7'), 131.13 (C-4a), 
129.54 (C-5), 128.19 (C-8'), 127.76 (C-6), 127.37 (C-6'), 125.44 (C-3), 123.87 (C-
5'),119.12 (C-4a'), 105.23 (C-3), 48.31 (C-c), 46.16 (C-a), 34.63 (C-b). Calc. for 
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N' -Quinolin-2-yl-methylene-l '-(3-
dimethylamino-l-propylamine)-thiosemicarbazone (49). Yield: 0.13 g; 55 %, 
obtained as a cream fluffy powder, mp: 195-197 °c (from ethanol), Rf (methanol: 
dichloromethane, 1:9) 0.14; Vmax (KBr)/ cm-
l 3134 (N-H), 2942 (C-H, aliphatic), 
1523 (C=C). 011(400 MHz, CDC]3) 9.32 (s, 1 H, NNH), 9.18 (s. ] H, NH), 8.15 (d, 1 H, 
J 8.4 Hz, H-4), 8.07 (dd, 1 H, J 1.5 and 8.4 Hz, H-8), 8.03 (d, 1 H, J 8.4 Hz, H-3), 7.98 
(s, I H, HC=N), 7.82 (dd, 1 H, J 1.5 and 8.4 Hz, H-5), 7.74 (ddd, 1 H, J 1.5, 7.2 and 8.4 
Hz, H-6), 7.57 (ddd, tH, J 1.5, 7.2 and 8.4 Hz, H-7), 3.87 (t, 2H, J 5.6 Hz, 2x Ha), 
2.52 (t, 2H, J 5.6 Hz, 2x He), 2.32 (s, 6H, N(CH3h), 1.85 (m, 2H, 2x Hb). oc(J 00 
MHz, CDCb).187.67 (C=S), 155.54 (HC=N), 145.19 (C-2), 141.95 (C-8a), 138.62 
(C-4), \37.21 (C-4a) 136.03 (C-7,C-8), 129.95 (C-5), 129.40 (C-6), 127.50 (C-3), 
59.29 (C-e), 45.71 (C-a), 45.53 N(C1-hh), 25.40 (C-b). Anal Found: C, 61.55; H, 
6.88; N, 21.27; S, 9.52 %. Calc. for C l6H21 N5S: C, 60.92; H, 6.71; N, 22.20; S, 10.17 
%. Calc. for C 16tbNsS, mlz 316.15958 (M+lf. Found HRMS (FAB) mlz 316.15913 
(M+lf. 
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6' N' -Quinolin-2-yl-methylene-l'-
(N' -(7 -chloro-q uinoline-4-yl] propane-l ,3-diamine )-thiosemicarhazone (50). 
Yield: 55 mg; 22 %, obtained as brownish powder after column chromatography 
(Si02, methanol: dichloromethane, 1 :9), mp: 209-212 °c (from ethanol), Rf 
(methanol: dichloromethane, 1:9) 0.40; Vrnax (KBr)/ em- l 3279 (N-H), 2937 (C-H, 
aliphatic), 1532 (C=C). 6H(400 MHz, CDCI 3). 8.49 (d, 1 H, J 5.6 Hz, H-2 '), 8.30 (d, 
I H, J 8.4 Hz, H-4), 8.26 (dd, I H, J 1.5 & 8.4 Hz, H-8), 8.13 (d,l H, J 8.4 Hz, H-5 ,), 
8.07 (d, lH, J 8.4 Hz, H-3), 8.03 (s, I H, HC=N), 7.94 (d, I H, J ].8 Hz, H-8 '), 7.9\ 
(dd, ttl, J 1.5 and 8.4 Hz, H-5), 7.83 (ddd, IH, J 1.5,7.2 and 8.4 Hz, H-6), 7.66 (ddd, 
I H, J 1.5, 7.2 and 8.4 Hz, H-7), 7.35 (dd, I H, .J 1.8 and 8.4 Hz, H-6), 6.43 (d, 1 H, J 











2H, 2x Hb). oc(lOO MHz, CDCb).187.32 (C=S), 155.63 (HC=N), 149.68 (C-2), 
149.43 (C-2'), 149.26 (C-4'), 148.63 (C-8a), 142.63 (C-8a), \39.21 (C-4), 136.7] 
(C-4a) 136.37 (C-7,C-8), 135.33 (C-7'), 130.95 (C-5), 129.65 (C-6), 128.19 (C-8'), 
127.63 (C-3), 127.37 (C-6), 123.87 (C-5'), 119.12 (C-4a'), 105.23 (C-3'), 47.52 (C-
e), 46.37 (C-a), 35.23 (C-b). Calc. for C23H2ICIN6S, mlz 449.13151 (M+ 1 r. Found 
HRMS (FAB) mlz 449.13076 (M+lf. 
General procedure for the preparation of compounds 40,45,47,60 and 62 
A solution of the appropriate quinolinecarboxaldehyde (1.0 equiv.) semicarbazide 
hydrochloride (1.0 equiv.) and triethylamine (0.31 ml) in methanol was stirred under 
reflux until a white precipitate started forming. It was then cooled to room 
temperature, filtered by suction and washed with cold methanol to afford the desired 
products. 
N'-Quinolin-4-yI-metbylene-seminarbazone (40). Yield: 
0.32 g; 78 %, obtained as a white powder, mp: 238-240 °C (from ethanol), Rf (Ethyl 
acetate: hexane, 4: 1) 0.34, Vmax (KBr)/ em'! 3463 (N-H, NH2), 3086 (C-H, aromatic), 
1700 (C=O), 1575 and C=N). 8[1(300 MHz. DMSO-d6) 10.62 (s, IH, NNH), 
8.92 (d, Iii. J 4.6 Hz, H-2), 8.63 (s, IH, HC=N), 8.36 (dd,IH, J2.0 and 8.2 Hz, H-8), 
8.08 (d, 1 H, J 4.6 Hz, H-3), 8.00 (dd, I H, J 2.0 and 8.2 Hz, H-5), 7.82 (ddd, I H, J 2.0, 
6.6 and 8.2 Hz, H-6), 7.71 (ddd, 1 H, J 2.0, 6.6 and 8.2 Hz, H-7), 6.68 (5, 2H, Nlh). 
8c(100 MHz, DMSO-d6) 156.96 (C=O), 150.46 (HC=N), 148.57 (C-2), 139.04 (C-
8a), 135.55 (C-4), 130.37 (C-8), 130.04 (C-7), 128.02 (C-4a), 125.50 (C-5), 124.01 
(C-6), 118.37 (C-3). Anal Found: C, 61.41; H, 4.69; S, 25.77 %. Calc. forC II HION40: 
C, 61.67; H, 4.71; N, 26.15 %. Calc. for C11 H ION40, m/z 214.08546 (MY. Found 
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N' -(2-Chlo ro-6-methyl)-q ui noli n -3-yl-methy lene-
semicarbazone (47). Yield: 0.17 g, 44 %, obtained as a white powder, mp: 274-276 
°c (from ethanol), RdEthyl acetate: hexane, 4: I) 0.43, Vmax (KBr)/ cm-I 3462 (N-H, 
NH2), 3160 (N-H), 1719 (C=O), 1660 (C=N), 1589 (C=C). bH(400 MHz, DMSO-d6) 
10,60 (s,1 H, NNH), 9.06 (s, 1 H, H-4), 8.25 (5, 1 H, HC=N), 7.83 (d, 1 H, J 8.6 Hz, H-
8), 7.75 (d, 1 H, J 2.0 Hz, H-5), 7.64 (dd, IH, J 2.0 and 8.6 Hz, H-7), 6.65 (s, 2H, 
NH2 ), 2.50 (s, 3H, 6-CH3). bc(lOO MHz, DMSO-d6 ) 157.12 (C=O), 155.30 (C-2) , 
153.34 (HC=N), 147.93 (C-8a), 146.02 (C-4), 138.05 (C-6), 135.26 (C-7), 134.88 (C-
8), 134.56 (C-5), 134.03 (C-4a), 128.12 (C-3), 21.83 (CH3) Anal Found: C, 54.27; H, 
4.20; N, 20.65 %. Calc. for C12H11CIN40: C, 54.87; H, 4.22; N, 21.33 %. Calc. for 
C 12H11 CIN40, mlz 262.06213 (Mr. Found HRMS (FAB) mlz 262.06213 (Mf. 
N' -(2-Ch loro-6-methoxy )-q uinolin-3-yl-
methylene-semicarbazone (45). Yield: 0.31 g, 76 %, obtained as a white powder, 
mp: 265-267 °c (from ethanol), Rf (Ethyl acetate: hexane, 4: 1) 0.38, Vrnax (KBr)/ em-I 
3479 (N-H, NH2), 3179 (N-H), 1713 (C=O), 1588 (C=C). bH(400 MHz, DMSO-d6) 
10.63 (s, I H, NNH), 9.06 (5, HI, H-4), 8.24 (5, 1 H, llC=N), 7.83 (d, 1 H, J 9.2 Hz, H-
8),7.44 (dd, tH, J2.8 and 9.2 Hz, H-7), 7.34 (d, IH, J2.8 Hz, H-5), 6.66 (s, 2H, 
NH2), 3.90 (s, 3H, OCH3). bc(100 MHz, DMSO-d6) 162.13 (C=O), 158.66 (C-6), 
157.12 (C-2), 156.20 (HC=N), 146.43 (C-8a), 143.45 (C-4), 134.68 (C-8), 134.55 (C-
4a), 129.84 (C-3), 124.34 (C-7), 106.55 (C-5), 56.28 (OCH3). Anal Found: C, 51.19; 
H, 3.92; N, 19.86 %. Calc. for CI2HIICIN402: C, 51.72; H, 3.98; N, 20.10 %. Calc. for 
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I 0 
N'NA NH 2 
H N'-Quinolin-2-yl-ethylene-semicarbazone (60). Yield: 
0.13 g; 48 %, obtained as an off-white powder, mp: 228-232 DC (from ethanol), Rf 
(ethyl acetate: hexane, 1:1) 0.11, Vmax (KBr)/ em'] 3473 (N-H, NH2), 3161 (N-H), 
1719 (C=O), 1583 (C=C and C=N) DH(400 MHz, DMSO-d6) 9.59 (s, IH, NNH), 8.48 
(d, t H, J 8.4 Hz, H-4), 8.26 (dd, 1 H, J 2.1 and 8.8 Hz, H-8), 8.00 (d, I H, J 8.4 Hz, H-
3),7.93 (dd, IH, J2.1 and 8.8 Hz, H-5), 7.72 (ddd, tH, J2.1, 7.0 and 8.8 Hz, H-6), 
7.56 (ddd, tH, J 2.1, 7.0 and 8.8 Hz, H-7), 6.72 (s, 2H, NH2), 2.40 (s, 3H, CH3)' 
DC (1 00 MHz, DMSO) 157.50 (C=O), 156.08 (CH3C=N), 147.40 (C-2), 145.64 (C-8a), 
136.40 (C-4), 130.21 (C-4a), 129.67 (C-8), 128.38 (C-7), 128.20 (C-5), 127.32 (C-6), 
119.21 (C-3), 11.88 (CH3). Calc for C12H12N40; mlz 228.10111 (M)'. Found HRMS 
(EI) mlz 228.10121 (M)'. 
N'-Quinolin-8-yl-ethylene-semicarbazone (62). Yield: 0.19 
g, 48 %, obtained as a white powder, mp: 177-179 °c (from ethanol), Rf (Ethyl 
acetate: Hexane, I: I) 0.32, Vmax (KBr)/ em'l 3464 (N-H, NH2), 3236 (N-H), 1683 
(C=O), 1577 (C=C). oH(400 MHz, DMSO-d6) 9.34 (5, IH, NNH), 8.90 (dd, IH, J2.0 
and 4.4 Hz, H-2), 8.38 (dd, 1 H, J2.0 and 8.4 Hz, H-4), 7.98 (dd, 1 H, J 1.6 and 8.4 Hz, 
H-5), 7.75(1, 1H,J8.4Hz,H-6), 7.59 (dd, IH,J 1.6 and 8.4 Hz, H-7), 7.54 (dd, IH,J 
4.4 and 8.4 Hz, H-3), 6.27 (s, 2H, NH2), 2.35 (s, 31-1, CH3 ). 8c(1 00 MHz, DMSO-d6) 
157.95 (C=O), 150.69 (ClhC=N), 148.74 (C-2), 146.37 (C-8a), 139.90 (C-4), 137.13 
(C-8), 129.81 (C-5), 129.33 (C-7), 128.73 (C-4a), 126.91 (C-6), 122.14 (C-3), 19.84 
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General procedure for the preparation of compounds 66 and 67 
A mixture of the appropriate 3-formylquinoline (1.0 equiv.), 2,4-
dichloroacetophenone (1.0 equiv.) and sodium methoxide (1.0 equiv.) in 6ml of 
ethanol was stirred at room temperature for 24 hrs. It was then filtered by suction and 
washed with water to afford the desired products. 
o 
3-(2-Chloro-6-methoxy-quinolin-3-yl)-1-(2,4-
dichloro-phenyl)-propenone (66). Yield: 1.50 g; 85 %, obtained as a yellow powder. 
mp: 176-178 °C (from methanol-water), Rf (ethyl acetate: hexane, 2:8) 0.35, Vmax 
(KBr)/ cm·l 3086 (C-H), 1666 (C=C), 1621 (C=C). 8!i(400 MHz. CDCb) 8.34 (s, 1H, 
H-4), 7.95(d, IH,JI6.0 Hz, Hp), 7.89(d, IH,J9.0 Hz, H-8), 7.52-7.49(m,2H,H-11 
& H-14), 7.43 (dd, IH, J2.7 and 9.0 Hz, H-7), 7.38 (dd, IH, J 1.6 and 8.6 Hz, H-13), 
7.22 (d, IH, J 16.0 Hz, Ha), 7.11 (d, IH, J 2.7 Hz, H-5), 3.94 (s, 3H, OCH3). 8c(75 
MHz, CDCh) 192.43 (C=O), 159.25 (C-6), 155.12 (C-2), 144.23 (C-8a), 141.41 (eft), 
138.45 (C-12), 137.83 (C-1O), 136.11 (C-9), 133.83 (C-4), 133.10 (C-14), 130.63 (C-
3), 130.53 (C-11), 130.10 (Ca), 129.34 (C-8), 128.23 (C-4a), 127.78 (C-13), 124.41 
(C-7), 106.47 (C-5), 58.53 (OCH3), Anal Found: C, 58.03; H, 2.70; N, 3.53 %.Calc. 
for Cl9H l2CbN02: C, 58.12; H, 3.08; N, 3.57 %. Calc. for C I9H12ChN02, mlz 
390.99336 (Mf. Found HRMS (EI) mlz 390.99338 (Mf. 
3-(2-Chloro-6-methyl-q uinolin-3-yl)-1-(2,4-
dichloro-phenyl)-propenone (67). Yield: 1.60 g; 87 %, obtained as a yellow powder, 
mp: 162-165 °C (from methanol-water), Rf (ethyl acetate: hexane, 2:3) 0.59, Vmax 
(KBr)/ em-I 3067 (C-H), 1654 (C=C), 1613 (C=C). 8!i(400 MHz, CDCb) 8.35 (5, IH, 
H-4), 7.95 (d, IH, J 16.0 Hz, Hp), 7.88 (d, IH, J9.6 Hz, H-8), 7.62 (d, IH, J8.4 Hz, 
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2.4 and 8.4 Hz, H-13), 7.24 (d, I H, J 16.0 Hz, Ha), 2.53 (s, 3H, 6-CH3)' oc(l 00 MHz, 
CDCh) 191.73 (C=O), 152.29 (C-2), 146.74 (C-8a), 140.91 (Cp), 137.99 (C-i2), 
137.50 (C-1O), 136.86 (C-6), 135.81 (C-9), 134.25 (C-4), 132.50 (C-i4), 130.70 (C-
7), 130.53 (C-3), 130.33 (C-11), 129.25 (Ca), 128.13 (C-13), 127.47 (C-8), 127.15 
(C-5), 126.94 (C-4a), 21.59 (6-CH3). Calc for Cl9HI2Cl3NO, mlz 375.99844 (Mf· 
Found HRMS (EI) mlz 375.99895 (Mf. 
General procedure for the preparation of compounds 68 and 69 
A solution of the appropriate chalcone (1.0 equiv.) and hydrazine hydrate (1.05 
equiv.) in 20ml of ethanol was stirred under reflux with TLC monitoring for 12 hrs. It 
was cooled to room temperature, then in ice to enhance precipitation. The crude was 
filtered and washed with cold methanol to afford the desired products. 
HN-N CI 
5 4 I \\~10 
Meo,~. ~~17 I ";11 
7U ~ 16 14 ~CI 
8 8a N CI 13 
1 2-Chloro-3-[5-(2,4-dichloro-phenyl)-3,4-
dihydro-2H-pyrazol-3-yIJ-6-methoxy-quinoline (68). Yield: 0.56 g; 54 %, obtained 
as an off-white powder. mp: 118-120 °c (from methanol), Rf (ethyl acetate: hexane, 
2:8) 0.19, Vmax (KBr)/ cm-
l 3347 (N-H), 3054 (C-H, aromatic), 2875 (C-H, aliphatic), 
1623 (C=C). oH(300 MHz, CDCb) 8.34 (s, 1 H, H-4), 7.91 (d, 1 H, J 9.6 Hz, H-8), 7.65 
(d, 1 H, J 8.4 Hz, H-14), 7.41 (d, 1 H, J 2.1 Hz, H-i1), 7.36 (dd, I H, J 2.7 and 9.6 Hz, 
H-7), 7.26 (dd, IH,J2.1 and 8.4 Hz,H-i3), 7.09(d, IH,J2.7 Hz,H-5), 6.22 (d, IH, 
J 3.0 Hz, NH), 5.40 (ddd, IH, J 3.0,10.2 and 16.5 Hz, H-I5), 3.92 (s, 3H, OCH3), 
3.88 (dd, IH, J 10.2 and 16.5 Hz, H-I6), 3.13 (dd, lH, J 10.2 and 16.5 Hz, H-I6). 
oc(75 MHz, CDCb) 158.45 (C-6), 153.76 (C-2), 149.74 (C-I7), 146.85 (C-8a), 
137.51 (C-I2), 135.13 (C-IO), 135.03 (C-9), 134.53 (C-4), 133.62 (C-I4), 130.88 (C-
3), 130.41 (C-II), 129.63 (C-8), 128.52 (C-13), 127.25 (C-4a), 123.20 (C-7), 105.24 
(C-5), 66.73 (OCH3), 55.63 (C-16), 42.61 (C-I5). Anal Found: C, 55.95; H, 3.01; N, 
10.16 %. Calc. for C19H14ChN30: C, 56.11; H, 3.47; N, 10.33 %. Calc. for 
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8 a 1 2-Cbloro-3-[5-(2,4-dichloro-phenyl)-3,4-dihydro-
2H-pyrazol-3-yI1-6-methyl-quinoline (69). Yield: 0.86 g; 83 %, obtained as a white 
powder, mp 130-133 °C (from methanol), Rr (ethyl acetate: hexane, 2:3) 0.57. Vmax 
(KBr)/ cm"1 3317 (N-H), 3034 (C-H, aromatic), 2905 (C-H, aliphatic), 1603 (C=C). 
6H(300 MHz, CDCh) 8.35 (s, t H, H-4), 7.91 (d, I H, J 8.4 Hz, H-8), 7.65 (d, 1 H, J 8.4 
Hz, H-14), 7.59 (d, tH, J 2.0 Hz, H-ll), 7.54 (dd, IH, J 2.0 and 8.4 Hz, H-7), 7.41 
(d, I H, J 2.0 Hz, H-5), 7.26 (dd, 1 H, .J 2.0 and 8.4 Hz, H-13), 6.18 (d, 1 H, J 3.0 Hz, 
NH), 5.40 (ddd, t H, .J 3.0, 10.2 and t 6.2 Hz, H-15), 3.90 (dd, 1 H, .J 10.2 and 16.2 Hz, 
H-l6), 3.13 (dd, tH, J 10.2 and 16.2 Hz, H-I6), 2.53 (s, 3H, 6-CH3). 15c(75 MHz, 
CDCh) 151.72 (C-2), 148.60 (C-17), 145.69 (C-8a), 137.47 (C-12), 137.30 (C-IO), 
136.37(C-6), 135.10 (C-9), 133.27 (C-4), 133.03 (C-14), 132.80 (C-7), 130.87 (C-3), 
130.38 (C-ll), 127.90 (C-13), 127.39 (C-8), 127.24 (C-5), 126.53 (C-4a), 61.74 (C-
16),42.53 (C-15), 21.60 (6-CH3). Anal Found: C, 58.12; H, 3.39; N, 10.74 %. Calc 
tor C19H14CbN3: C, 58.41; H, 3.61; N, 10.76 %. Calc. tor CI9HI4ChN3, mlz 
389.02533 (M)'. Found HRMS (EI) mlz 389.02534 (Mf. 
General procedure for the preparation of compounds 75-84 
A solution of pyrazoline derivative 68/69 (1.0 equiv.) and the appropriate substituted 
phenyl sulfonyl urea (2.0 equiv.) in 1 mt ofTHF was stirred at room temperature with 
TLC monitoring for 3 hrs. The products precipitated out of solution and were filtered 
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8 1 N-[5-(2-Chloro-6-methoxy-quinolin-3-yl)-3-
(2,4-dichloro-phenyl)-4,5-dihydro-pyrazole-l-carbonyIJ-benzenesulfonamide 
(75). Yield: 55 mg; 38 %, obtained as a white flaky powder mp: 229-230 °c (from 
ethyl acetate-hexane), Rf (Methanol: Dichloromethane, 1:50) 0.44. Vmax (KBr)/ cm-
1 
3304 (N-H), 3053 (C-H, aromatic), 2922 (C-H, aliphatic), 1692 (C=O), 1627 (C=C). 
bH(400 MHz, CDCb) 8.81 (s,IH, Nfl), 8.10 (dd, 2H, 12.0 and 8.4 Hz, H-19 and H-
23),7.87 (d, IH, 19.2 Hz, H-8), 7.71 (s, IH, H-4), 7.64 (t, 2H, J8.4 Hz, H-20 and H-
22), 7.54-7.50 (m, 2H, H-21 and H-14), 7.46 (d, lR J2.0 Hz, H-ll), 7.37 (dd, IH, J 
2.0 and 8.4 Hz, H-J3), 7.30 (dd, 1 H, J2.8 and 9.2 Hz, H-7), 7.01 (d, I H, 12.8 Hz, H-
5), 5.82 (dd, 1 H, J 12.4 and 18.4 Hz, H-15), 4.16 (dd, 1 H, J 12.4 and 18.4 Hz, H-l6), 
3.92 (s, 3H, OClh), 3.34 (dd, I H, J 12.4 and 18.4 Hz, H-16), <5c(75 MHz, CDCh) 
161.21 (C=O), 158.75 (C-6), 154.98 (C-2), 153.57 (C-17), 143.50 (C-8a), 139.17 (C-
18),137.48 (C-12), 135.92 (C-1O), 135.03 (C-9), 134.02 (C-4), 131.42 (C-14), 131.25 
(C-3), 130.88 (C-21), 129.78 (C-JI), 129.14 (C-8), 128.64 (C-20, C-22), 127.82 (C-
13), 127.97 (C-4a), 125.33 (C-19, C-23), 123.83 (C-7), 105.67 (C-5), 58.49 (OCH3), 
55.90 (C-16), 45.00 (C-15). Anal Found: C, 52.83; H, 3.14; N, 9.50; 5.02 %. Calc. for 
C26HI9CbN404S: C, 52.94: H, 3.25; N, 9.50; S, 5.44 %. Calc. for C:~6HI9CbN404S, 
mlz 589.02708 (M+l)'. Found HRMS (FAB) mlz 589.02754 (M+lf. 
N-[5-(2-Chloro-6-methyl-quinoHn-3-yl)-3-(2,4-
dichloro-phenyl)-4,5-dihydro-pyrazole-l-carbonyl]-benzenesulfonamide (76). 
Yield: 84 mg, 57 %, obtained as a white flaky powder, mp: 217-220 °c (from ethyl 
acetate-hexane), Rf (ethyl acetate: hexane, 1:1) 0.35. Vmax (KBr)/ cm-
1 3294 (N-H), 
3097 (C-H, aromatic), 2872 (C-H, aliphatic), 1683 (C=O), 1586 (C=C). oH(400 MHz, 
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8.8 Hz, H-8), 7.70 (s, 1 H, H-4), 7.65 (d, 1 H, J 8.8 Hz, H-14), 7.60 (dd, 1 H, J 2.0 and 
8.8 Hz, H-7), 7.56 (d, IH, J 2.0 Hz, H-5), 7.54-7.49 (m, 3H, H-J3, H-20, H-22), 7.46 
(d, J H, J 2.0 Hz, and H-ll), 7.32 (dd, 1 H, J 2.0 and 8.8 Hz, H-2l), 5.83 (dd, I H, J 
12.0 and 18.0 Hz, H-I5), 4.16 (dd, IH, J 12.0 and 18.0 Hz, H-I6), 3.34 (dd, IH, J 
12.0 and 18.0 Hz, H-I6), 2.51 (s, 3H, 6-CH3)' oc(100 MHz, CDCh) 162.33 (C=O), 
152.42 (C-2), 148.53 (C-/7), 145.19 (C-8a), 139.32 (C-18), 138.27 (C-I2), 137.50 
(C-IO), 136.53 (C-6), 134.98 (C-9), 133.34 (C-4), 133.12 (C-14), 132.78 (C-7), 
131.43 (C-21), 131.17 (C-3), 130.48 (C-1I), 128.63 (C-20, C-22), 128.13 (C-I3), 
127.49 (C-8), 127.13 (C-5), 126.91 (C-I9, C-23), 126.64 (C-4a), 58.51 (C-I6), 44.97 
(C-I5), 21.75 (6-0h). Anal Found: C, 54.27; H, 3.08; N, 9.54; S, 5.87 %. Calc for 
C26H l9CbN40 3S: C, 54.42; H, 3.34; N, 9.76; S, 5.59 %. Calc for C26H19CbN403S, mlz 
574.03999 (M+lf. Found HRMS (FA B) mlz 574.03964 (M+1f. 
23 0 
22a/~8 \l:r:::O P 
I ' .-11 
---21" -19 N 'N-N CI 
20 5 4H I \ 9 10 
MeO 6. ':/ 4 ~3 5 7 I 11 
I . 16 
7~ ~ 14 4 CI 
8 8a N CI 13 
1 N-[5-(2-Chloro-6-metboxy-quinolin-3-yl)-3-
(2,4-dichloro-phenyl)-4,5-dibydro-pyrazole-l-carbonyl]-4-metbyl-
benzenesulfonamide (79). Yield: 83 mg; 57 %, obtained as white flaky powder, mp: 
219-222°C (from ethyl acetate-hexane), Rf (ethyl acetate: hexane, 1:1) 0.48. Vmax 
(KBr)/ cm'l 3354 (N-H), 3076 (C-H, aromatic), 2856 (C-H, aliphatic), 1696 (C=O), 
1590 (C=C). oH(400 MHz, CDCb) 8.83 (s, tH, NH), 7.98 (d, 2H, J 8.4 Hz, H-19 and 
H-23), 7.86(d, IH,J9.2Hz,H-8), 7.73(s, IH,H-4), 7.65 (d,2H,J8.4Hz,H-20and 
H-22), 7.45 (d, 1 H, J 2.0 Hz, H-ll), 7.37 (dd, 1 H, J 2.4 and 9.2 Hz, H-7), 7.32 (dd, 
IH, J2.0 and 8.4 Hz, H-13), 7.29 (d, IH, J 8.4 Hz, H-14), 7.03 (d, 1 H, J2.4 Hz, H-5). 
5.82 (dd, IH, J 12.0 and 18.0 Hz, H-15), 4.14 (dd, tH, J 12.0 and 18.0 Hz, If-I6), 
3.91 (s, 3H, OCH3), 3.33 (dd, IH, J 12.0 and 18.0 Hz, H-I6), 2.41 (s, 3H, 21-CH3). Oc 
(l00 MHz, CDCh) 160.03 (C=O), 158.72 (C-6), 155.08 (C-2), 153.46 (C-/7), 143.48 
(C-8a), 140.27 (C-21), 137.43 (C-12), 136.18(C-18), 135.92 (C-IO), ]33.78 (C-4), 
131.44 (C-14), 131.21 (C-3), 129.88 (C-ll), 129.77 (C-20, C-22), 129.06 (C-9), 
]28.68 (C-8), 127.81 (C-13), 127.47 (C-4a), 124.73 (C-19, C-23), 123.73 (C-7), 











Chapter 5 Experimental 
C, 53.71; H, 3.84; N, 8.88; S, 5.28 %. Calc. for C27H21CbN404S: C, 53.70; H, 3.50; 
N, 9.28; S, 5.31 %. Calc. for C27H2ICbN404S, mlz 604.05056 (M+ 1)". Found HRMS 
(FAB) mlz 604.05096 (M+lf· 
22 23 q\ 0 
lJ!i1fis-:NO~ CI 
~~9 N-N 
20 5 4 4i 15 \ .§lriAg11 
';:/ I ~3 17 II _i 
7~ "X 16 14'~'CI 
8 8a N1 2 CI 13 
N -( 5-(2-C h 10 ro-6-m ethyl-q u i nolin-3-yl)-3-(2,4-
dichloro-phenyl)-4,5-dihydro-pyrazole-l-carbonyIJ-4-methyl-
benzenesulfonamide (80). Yield: 96 mg, 64 %, mp: 217-219 °c (from ethyl acetate-
hexane) obtained as a white powder. Rr (ethyl acetate: hexane, 1: 1) 0.50. Vmax (KBr)/ 
cm·1 3316 (N-H), 3034 (C-H, aromatic), 2986 (C-H, aliphatic), 1682 (C=O), 1602 
(C=C). oH(400 MHz, CDCb) 8.85 (s, 1 H, NIl), 7.97 (d, 2H, J 8.4 Hz, H-19, H-23), 
7.86 (d, 1 H, J 8.8 Hz, H-8), 7.69 (s, IH, H-4), 7.65 (d, IH, J 8.4 Hz, H-14), 7.55 (dd, 
1 H, J 2.0 and 8.8 Hz, H-7) 7.49 (d, tH, J 2.0 Hz, H-5), 7.44 (d, 1 H, J2.0 Hz, H-J n 
7.30 (dd, IH, J 2.0 and 8.4 Hz, H-13), 7.28 (d, 2H, J 8.4 Hz, H-20 and H-22), 5.82 
(dd, 1 H, J 12.0 and 18.0 Hz, H-J5), 4.13 (dd, 1 H, J 12.0 and 18.0 Hz, H-J6), 3.34 (dd, 
1H, J 12.0 and 18.0 Hz, H-I6), 2.50 (s, 3H, 6-CH3), 2.40 (s, 3H, 21-CH3). &:(100 
MHz, CDCb) 161.76 (C=O), 154.32 (C-2), 153.44 (C-/7), 145.07 (C-8a), 141.06 (C-
21), 137.80 (C-18), 137.41 (C-12), 136.22 (C-6), 134.44 (C-IO), 133.99 (C-4), 131.46 
(C-14), 131.17 (C-3), 130.97 (C-9), 130.34 (C-20, C-22), 130.18 (C-ll), 129.76 (C-
7), 128.67 (C-13), 127.24 (C-5), 126.87 (C-4a), 125.02 (C-/9, C-23), ]24.13 (C-8), 
58.52 (C-I6), 44.98 (C-15), 21.84 (21-Cl·h), 21.76 (6-Cf-h). Calc. for 














22r~8 \\S-:::O ;? 
'I'r 'N~ CI 2t~J19 H N--N I 
20 5 4 f \L !t:t10 MeO~~:h3 5'-A7-1 ~11 
7l" 11 2 16 14 ~ 
Experimental 
~N~ CI 13 1 CI 
8 1 N-[ 5-(2-Chloro-6-methoxy-q uinolin-3-yl)-3-
(2,4-dichloro-phenyl)-4,5-dihydro-pyrazole-t -carbonyl,]-2-methyl-
benzenesulfonamide (77). Yield: 82 mg; 85 %, obtained as white flaky powder, mp: 
213-215 °c (from ethyl acetate-hexane), Rf (ethyl acetate: hexane, 1: I) 0.45. Vrnax 
(KBr)/ cm- l 3403 (N-H), 3097 (C-H, aromatic), 2882 (C-H, aliphatic), 1685 (C=O), 
1622 (C=C). oH(400 MHz, CDCb) 8.87 (5, 1 H, NH), 8.16 (d, J H, J 8.8 Hz, H-8), 7.86 
(d, IH,J9.6 Hz, H-19), 7.72(s, IH,H-4), 7.63(d, IH,J9.6 Hz, H-22), 7.50(d, IH,J 
1.2 Hz, H-ll), 7.48 (t, IH, J 9.6 Hz, H-20), 7.37-7.31 (m, 4H, H-7, H-13, H-14, H-
21),7.03 (d, lRJ2.4 Hz, H-5), 5.80 (dd, IH,J 12.0 and 18.0 Hz, H-15), 4.15 (dd, 
IH, J 12.0 and 18.0 Hz, H-I6), 3.92 (5, 3H, OCH3), 3.35 (dd, IH, J 12.0 and 18.0 Hz, 
H-I6), 2.74 (5, 3H, 23-CH3). oc(IOO MHz, CDCb) 159.98 (C=O), 156.68 (C-6), 
155.08 (C-2), 153.48 (C-I7), 143.48 (C-8a), 140.01 (C-18), 137.48 (C-I2), 134.09 
(C-I0), 132.60 (C-4), 131.56 (C-23), 131.39 (C-14), 131.32 (C-2I), 129.98 (C-11), 
129.77 (C-3), 129.12(C-9), 128.46 (C-22), 128.25 (C-8), 127.84 (C-13), 126.67 (C-
4a), 125.60 (C-20), 123.83 (C-19), 121.37 (C-7), 105.27 (C-5), 58.44 (OCH3), 55.90 
(C-I6), 44.96 (C-I5), 20.69 (23-CH3). Anal Found: C, 53.82; H, 3.42; N, 9.33; S, 5.51 
%. Calc. for C27H21CbN404S: C, 53.70; H, 3.50; N, 9.28; S, 5.31 %. %. Calc. for 




71/'~"18\S-:::O, 0 21// - , .-lI 
,, __ 9 N "N CI 
20 .H N- ~ 110 
54 4' 15 \ V~11 
171 1 
71, II 3 16 ~
~~/2 CI 14 13 12 CI 
N-[5-(2-Chloro-6-methyl-quinolin-3-yl)-3-(2,4-
dichloro-phenyl)-4,5-dihydro-pyrazole-l-carbonyl]-methyI-benzenesulfonamide 
(78). Yield: 18 mg, 12 %, obtained as white flaky powder, mp: 213-214 °c (from 
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H), 3039 (C-H, aromatic), 2943 (C-H, aliphatic), 1688 (C=O), 1522 (C=C). bH( 400 
MHz, CDCh) 8.86 (s, 1 H, NH), 8.15 (d, 1 H, J 8.4 Hz, H-8), 7.86 (d, 1 H, J 8.4 Hz, H-
19), 7.70(s, IH,H-4), 7.63(d, IH,.18.4Hz,H-22), 7.56(d, IH,.18.8Hz,H-14), 7.55 
(dd, 1 H, J2.0 and 8.4 Hz, H-7), 7.52 (d, 1 H, .12.0, H-S), 7.48 (d, 1 H, J2.0 Hz, H-ll), 
7.46 (t, 1 H, .1 8.4 Hz, H-20), 7.35 (dd, 1 H, J 2.0 and 8.8 Hz, H-13), 7.32 (t, 1 H, .1 8.4 
Hz, H-2n 5.8 1 (dd, IH,.1 12.0 and 18.0 Hz, H-lS), 4.15 (dd, IH, J 12.0 and 18.0 Hz, 
H-l6), 3.36 (dd, IH, J 12.0 and 18.0 Hz, H-l6), 2.75 (s, 3H, 23-Phe-CH3), 2.52 (s, 
3H, 6-CH3)' bH(100 MHz, CDCh) 162.36 (C=O), 153.92 (C-2), 153.54 (C-l7), 
144.77 (C-8a), 141.43 (C-18), 137.65 (C-12), 135.92 (C-6), 135.43 (C-23), 134.87 
(C-lO), 134.49 (C-4), 132.36 (C-14), 131.76 (C-21), 131.56 (C-3), 131.34 (C-9), 
130.74 (C-22), 130.56 (C-7), 130.28 (C-ll), 129.17 (C-13), 127.54 (C-S), 127.07 (C-
4a), 126.80 (C-20), 125.54 (C-19), 124.43 (C-8), 58.60 (C-l6), 45.48 (C-1S), 21.65 
(6-CH3), 20.65 (23-CHJ). Anal Found: C, 54.90; H, 3.17; N, 9.21; S, 5.49 %. Calc for 
C27H2ICbN403S: C, 55.16; H, 3.60; N, 9.53; S, 5.45 %. Calc. for C27H2IC13N403S, 
mJz 588.05564 (M+lf. Found HRMS (FAB) mlz 588.05594 (M+lf. 
23 a 
,,~~s~a I? 
CI~19 'N-'\N_N CI 
Mea 2~ 4 ~ 1 \ I ,,:0 11 
I 316 17 
7~ N""'2 CI 14 °12 C1 
8 8a 13 
I N-( 5-(2-Chloro-6-methoxy-quinolin-3-yl)-3-
(2,4-d ichlo ro-phenyl)-4,5-d ihyd ro-pyrazole-l-carbonyIJ-4-ch 10 ro-
benzenesulfonamide (81). Yield: 92 mg; 60 %, obtained as white flaky powder. mp: 
235-236 °c (from ethyl acetate-hexane), Rf (ethyl acetate: hexane, ]: I) 0.51. Vrnax 
(KBr)! cm'l 3348 (N-H), 3005 (C-H, aromatic), 1689 (C=O), 1578 (C=C). bH(400 
MHz. CDCb) 8.76 (s, 1 H, NH), 8.04 (d, 2H, J 8.8 Hz, H-19, H-23), 7.88 (d, I H, J9.2 
Hz, H-8), 7.71 (s, lH, H-4), 7.62 (d, 2H, J8.8 Hz, H-20, H-22), 7.48 (d, IH, J2.0 Hz, 
H-ll), 7.39 (dd, IH, .12.4 and 9.2 Hz, H-7), 7.35 (dd, tH, J2.0 and 8.4 Hz, 1I-13), 
7.28 (d, lH, .18.4 Hz, H-14), 7.02 (d, tH, J2.4 Hz, H-S), 5.82 (dd, lH, J 12.0 and 
18.0 Hz, H-JS), 4.14 (dd, IH, J 12.0 and 18.0 Hz, H-16), 3.92 (s, 3H, OCH3), 3.36 
(dd, 1H, J 12.0 and 18.0 Hz, H-l6). oc(IOO MHz, CDCI3) 159.83 (C=O), 158.91 (C-
6), 154.98 (C-2), 153.69 (C-17), 143.58 (C-8a), 140. 75 (C-21), 137.75 (C-18), 
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9),130.08 (C-11), 129.86 (C-20, C-22), 129.40 (C-8), 128.47 (C-13), 127.80 (C-4a), 
127.05 (C-19, C-23), 123.78 (C-7), 105.63 (C-5), 58.61 (OCH3), 55.85 (C-16), 
45.03(C-t5). Calc. for C26HlsC14N404S, mlz 623.99593 (M+tf. Found HRMS 
(FAB) mlz 623.99564 (M+lf. 
22 23 0\ ° 
21/0~s;::0~ 
CI-~d9 N N-N CI 
20 5 jl i -I~ 9 J1 0 
U
4~~~11 
I 13 16 ,I I 
7~ '" A 14~'CI 
8 8a N 2 CI 13 
1 4-Chloro-N-[S-(2-chloro-6-methyl-quinolin-3-
y I )-3-(2,4-dichlo ro-phenyl)-4,S-dihyd ro-pyrazole-l-carbonyl)-
benzenesulfonamide (82). Yield: 80 mg, 52 %, obtained as white flaky powder, mp: 
233-234 °C (from ethyl acetate-hexane), Rf (ethyl acetate: hexane, J: I) 0.27. Vmax 
(KBr)/ cm-1 3412 (N-H), 3091 (C-H, aromatic), 2856(C-H, aliphatic), 1681 (C=O), 
1532 (C=C). bH(400 MHz, CDCh) 8.79 (s, IH, Nil), 8.04 (d, 2H, J8.4 Hz, H-J9, H-
23), 7.88 (d, 1 H, J 8.8 Hz, H-8), 7.67 (s, 1 H, H-4). 7.64 (d, 1 H, J 8.4 Hz, H-14), 7.56 
(dd, IH,J 1.6 and 8.8 Hz,H-7), 7.50(d, IH,J1.6Hz,H-5), 7.48(d, IH,J2.0Hz,H-
11), 7.46 (dd, 1 H, J 2.0 and 8.4 Hz, H-13), 7.33 (d, 2H, J 8.4 Hz, H-20, H-22), 5.83 
(dd, IH, J 12.0 and 18.0 Hz, H-15), 4.16 (dd, IH, J 12.0 and 18.0 Hz, H-16), 3.37 (dd, 
IH, J 12.0 and 18.0 Hz, H-16), 2.53 (s, 3H, 6-CH3)' bc(100 MHz, CDCh) 161.37 
(C=O), 155.76 (C-2), 155.64 (C-17), 146.09 (C-8a), 140.78 (C-18), 137.98 (C-12), 
137.56 (C-21), 135.35 (C-6), 134.43 (C-1O), 134.06 (C-4), 131.40 (C-14), 131.26 (C-
3),130.78 (C-9), 130.54 (C-11), 130.18 (C-7), 129.84 (C-20, C-22), 129.47 (C-13), 
128.10 (C-19, C-23), 127.84 (C-5), 127.26 (C-4a), 126.80 (C-8), 58.53 (C-16), 44.99 
(C-15), 21.80 (6-CH3). Anal Found: C, 51.29; H, 2.69; N, 9.19; S, 5.13 %. Calc for 
C26HlsC14N403S: C, 51.33, H, 2.98; N, 9.21; S, 5.27 %. Calc. for C26H18Cl4N403S, 
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2/23 0 0 
2~~S~O~ CI 
F~19 H N-N 0 
MeO 20 i:l 4 15 \ q "':: 1 1 
6 I "':: 3 16 114 1 h 
7 ~ 8 N/. 2 CI 13 12 CI 
8 a 1 N-[5-(2-Chloro-6-methoxy-quinolin-3-yl)-3-
(2 ,4-d ich loro-pheny 1)-4,5-dih yd ro-pyrazole-l-ca rbony J) -4-fluo ro-
benzenesulfonamide (83). Yield: 13.33 mg; 9.1 %, obtained as a white flaky powder. 
mp: 226-227 °c (from ethyl acetate-hexane), Rr(ethyl acetate: hexane, 1:1) 0.52. Vmax 
(KBr)! cm- I 3376 (N-H), 3078 (C-H, aromatic), 2909 (C-H, aliphatic), 1701 (C=O), 
1576 (C=C). oH(400 MHz, CDCb) 8.80 (s, I H, NH), 8.13 (d, 2H, J 8.8 Hz, H-19, H-
23),7.88 (d, IH, J9.2 Hz, H-8), 7.7] (5, IH, H-4), 7.64 (d, 2H, J8.8 Hz, H-20, H-22), 
7.47(d, IH,J2.0Hz,H-ll), 7.38 (dd, IH,J2.4and 9.2 Hz,H-7) 7.32 (dd, IH,J2.0 
and8.4Hz,H-13), 7.21 (d, IH,J8.4Hz,H-14), 7.02(d, IH,J2.4Hz,H-5),5.82(dd, 
IH, J 12.0 and \8.0 Hz, H-15), 4.16 (dd, IH, J 12.0 and 18.0 Hz, H-I6), 3.92 (5, 3H, 
OCfh), 3.36 (dd, IH, J 12.0 and 18.0 Hz, H-I6). 8c(100 MHz, COCh) 167.33 (C-21), 
160.23 (C=O), 158.82 (C-6), 155.06 (C-2), 153.74 (C-I7), 143.51 (C-8a), 138.05 (C-
18),137.54 (C-12), 133.92 (C-I0), \33.80 (C-4), 131.72 (C-14), 131.62 (C-3), 131.42 
(C-9), 130.36 (C-l1), 129.81 (C-8), 128.46 (C-13), 127.83 (C-19, C-23), 127.73 (C-
4a), 123.92 (C-7), 116.54 (C-20, C-22), 105.48 (C-5), 58.52 (OCH3), 55.87 (C-I6), 
45.02 (C-15), Anal Found: C, 51.38; H, 2.69; N, 9.19; S, 5.18 %. Calc. for 
C26H18CbFN404S: C, 51.37; H, 2.98; N, 9.22; S, 5.28 %. Calc. for C26H18CbFN404S, 
mlz 607.12559 (M+lf. Found HRMS (FAB) mlz 607.13447 (M+lf. 
N-/5-(2-Chloro-6-methyl-quinolin-3-yl)-3-(2,4-
dichloro-phenyl)-4,5-dihydro-pyrazole-l-carbonyIJ-4-fluoro-benzenesulfonamide 
(84). Yield: 0.112 g, 74 %, obtained as white flaky powder, mp: 219-221 °c (from 
ethyl acetate-hexane), Rr(ethyl acetate: hexane, 1:1) 0.35. Vmax (KBr)! cm-
1 3309 (N-
H), 3090 (C-H, aromatic), 2950 (C-H, aliphatic), 1643 (C=O), 1688 (C=C). OH( 400 
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Hz, H-8), 7.67 (s, I H, H-4), 7.64 (d, 1 H, J 8.8 Hz, H-14), 7.56 (dd, I H, J 2.0 and 8.8 
Hz, H-7), 7.48 (d, IH, J 2.0 Hz, H-5), 7.46 (d, lH, J 2.0 Hz, H-ll), 7.33 (dd, tH, J 
2.0 and 8.8 Hz, H-13), 7.20 (d, 2H, J 8.8 Hz, H-20, H-22), 5.83 (dd, 1 H, J 12.0 and 
18.0 Hz, H-/5), 4.16 (dd, IH, J 12.0 and 18.0 Hz, H-16), 3.36 (dd, lH, J 12.0 and 
18.0 Hz, H-/6), 2.52 (s, 3H, 6-CH3)' oc(100 MHz, CDCh) 163.00 (C-2/), 160.97 
(C=O), 153.76 (C-2), 153.70 (C-17), 144.15 (C-8a), 137.96 (C-/8), 137.54 (C-12), 
135.56 (C-6), 134.41 (C-/O), 133.78 (C-4), 131.69 (C-14), 131.57 (C-3), 131.41 (c-
9), 130.69 (C-ll), 129.75 (C-7), 128.53 (C-13), 127.83 (C-19, C-23), 127.24 (C-5), 
126.82 (C-4a), 123.92 (C-8), 116.54 (C-20, C-22), 58.52 (C-16), 44.98 (C-/5), 21.73 
(6-Cl-i). Calc. for C26H1SCbFN403S, mJz 592.03057 (M+lf. Found HRMS (FAB) 
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